REGULATION OF NCX3 EXPRESSION BY HISTONE DEACETYLASES (HDACS) IN CORTICAL NEURONS AND IN BRAIN ISCHEMIA by Laudati, Giusy
“FEDERICO II” UNIVERSITY OF NAPLES 
SCHOOL OF MEDICINE 
 
 
 
PHD PROGRAM IN NEUROSCIENCE 
XXVIII CYCLE 
 
PhD THESIS WORK: 
REGULATION OF NCX3 EXPRESSION BY HISTONE 
DEACETYLASES (HDACS) IN CORTICAL NEURONS 
AND IN BRAIN ISCHEMIA 
 
COORDINATOR: PROF. LUCIO ANNUNZIATO 
 
TUTOR:                                                                  CANDIDATE:                                                                                       
DR LUIGI FORMISANO                                   GIUSY LAUDATI 
 
2014-2015 
ii 
 
 
iii 
 
INDEX 
 
Summary ........................................................................................................... 1 
 
 
Introduction 
I.A. PATHOPHYSIOLOGY OF CEREBRAL ISCHEMIA ................................... 2 
I.A.1. Excitotoxicity and ionic imbalance ....................................................... 2 
I.A.2. Oxidative and nitrosative stress  .......................................................... 4 
I.A.3. Apoptosis ............................................................................................ 4 
I.A.4. Inflammation  ....................................................................................... 6 
 
 
I.B. EPIGENETICS ........................................................................................... 7 
I.B.1. Nucleosome ........................................................................................ 7 
I.B.2. Epigenetic modifications ...................................................................... 8 
I.B.3. Acetylation and deacetylation ............................................................ 10 
I.B.4. Histone Acetyltransferase (HAT) Families ......................................... 11 
I.B.5. Histone Deacetylases (HDACs): Structure-Function Analysis ............ 12 
I.B.5.1. HDAC family members...................................................... ……13 
I.B.5.2 Sirtuin Family Members ..................................................... ……14 
I.B.6. HDACs inhibitors ............................................................................... 15 
I.B.7. Neuroprotection by HDAC Inhibition in Cellular Models ..................... 16 
I.B.7.1. Huntington’s Disease (HD) ....................................................... 19 
I.B.7.2. Parkinson’s Disease ................................................................ 19 
I.B.7.3. Alzheimer’s disease ................................................................. 20 
I.B.7.4. Amyotrophic Lateral Sclarosis (ALS) ........................................ 22 
I.B.8. HDAC Inhibition in Animal Models of cerebral ischemia .................... 23 
 
I.C. SODIUM CALCIUM EXCHANGER ........................................................... 25 
I.C.1. State of Art of NCX1, NCX2 and NCX3 isoforms ............................... 26 
I.C.2. Distribution of NCX isoforms in different tissues  ............................... 28 
iv 
 
I.C.3. Molecular Biology of NCX3 ................................................................ 29 
I.C.4. Identification of NCX3 minimal promoter sequence ........................... 31 
 
 
I.D. PUTATIVE TRANSCRIPTION FACTORS REGULATING NCX3 AND THEIR 
ROLE IN NEUROPATHOLOGICAL CONDITIONS .................................................. 34 
I.D.1. CREB ................................................................................................................ 34 
I.D.2. DREAM ............................................................................................................ 35 
I.D.3. SP transcription family factors ...................................................................... 37 
I.D.4. Structural Characteristics of the Sp Factors. .............................................. 38 
I.D.5. Early growth response-1 (EGR-1)................................................................ 40 
I.D.6. Activator protein 2 (AP-2)  ............................................................................. 40 
 
I.E. PHARMACOLOGICAL REGULATION OF NCX3  EXCHANGER 
ACTIVITY ....................................................................................................................... 41 
I.E.1. Inhibitors ........................................................................................................... 41 
I.E.2. Activators ......................................................................................................... 44 
 
I.F. ROLE OF NCX3 EXCHANGER IN PATHOPHYSIOLOGICAL CONDITIONS
 .......................................................................................................................................... 46 
 
I.G. TRANSCRIPTIONAL REGULATION OF NCX3 GENE IN NEURONS AND 
NEURONAL CELLS ....................................................................................................... 48 
I.G.1. Regulation of NCX3 promoter activity by DREAM in cerebellar neurons
 ................................................................................................................................ 48 
I.G.2. Regulation of NCX3 promoter activity by CREB in SH-SY5Y cell line ... 50 
 
I.H. MODULATION OF NCX3 EXPRESSION IN IN VIVO AND IN IN VITRO 
MODELS OF STROKE ................................................................................................. 52 
I.H.1. NCX3 gene is downregulated in brain ischemia and upregulated in 
postconditioned ischemic brain  ......................................................................... 52 
I.H.2. NCX3 sumoylation participates in SUMO1 protective role during 
ischemic preconditioning..................................................................................... 53 
I.H.3. OGD/Reoxygenation - induced NCX3 downregulation at post-
transcriptional level .............................................................................................. 55 
 
v 
 
Aim of the Study 
II. AIM OF THE STUDY ................................................................................. 56 
 
Matherials and Methods 
     III.1 Matherials................................................................................................58 
III.2. Primary Cortical Neurons ...................................................................... 58 
III.3. Transfection with Expression Plasmids Small Interfering RNA (siRNA) 
and Luciferase Reporter Assay, in Cortical Neurons  .................................... 59 
III.4. Quantitative Real-Time PCR (qRT-PCR) Analysis ................................. 59 
III.5. Western Blotting  ................................................................................... 60 
III.6. Chromatin Immunoprecipitation (ChIP)  ................................................. 61 
III.7. Experimental groups  ............................................................................ 62 
III.8. Transient Focal Ischemia  ..................................................................... 62 
III.9. Statistical analysis  ................................................................................ 63 
Results 
IV.1 HDAC class II A inhibitor MC1568 increases ncx3 promoter activity  ..... 64 
IV.2. MC1568 increases ncx3 luciferase activity in time - dependent manner 65 
IV.3. MC1568 regulates ncx3 promoter activity via DREAM sequence .......... 66 
IV.4. HDAC class IIA isoforms 4 and 5 reduce NCX3 mRNA and protein 
expression ..................................................................................................... 68 
IV.5. DREAM, HDAC4 and HDAC5 protein expression  is increased in brain 
ischemia ........................................................................................................ 70 
IV.6. Stroke induces an increase of HDAC4 and HDAC5 binding on ncx3 
promoter........................................................................................................ 71 
 
Discussion 
V. Discussion ................................................................................................. 73 
 
References 
VI. References ............................................................................................... 76 
 
  
 
 
 
 
 
 
 
Summary 
 
 
 
 
 
 
 
 
 
 
1 
 
SUMMARY  
Na+- Ca2+ exchanger isoform 3 (NCX3) plays a fundamental role in the 
pathogenesis of stroke damage. Indeed its ablation worsens the 
experimentally-induced ischemic damage. Interestingly it has been found 
that NCX3 mRNA and protein are both reduced after stroke. However, the 
mechanism by which stroke-induced ncx3 gene reduction is still unclear. 
Notably, in the last decades it has been found that histone deacetylases 
(HDACs) inhibition by regulating specific neuroprotective genes 
ameliorates the neurodegeneration that occurs in brain ischemia.  
Interestingly, we found that neurons treated with Trichostatin A (TSA), a 
pan HDACs inhibitor (HDACi), and MC1568, a class II HDACs inhibitor, 
significantly increased ncx3 promoter activity, whereas MS-275 (class I 
HDACs inhibitor) had no significant effect. Notably, among the HDACs 
class II A, we found that when the HDAC4 and HDAC5 isoforms were 
overexpressed by construct transfection or knocked-down by small 
interfering RNA (siRNA) transfection, NCX3 mRNA and protein levels were 
downregulated or increased, respectively. Moreover, experiments of site 
direct mutagenesis of DREAM (downstream regulatory element antagonist 
modulator) consensus sequence on ncx3 promoter in MC1568 treated 
neurons, corroborated that NCX3 downregulation induced by HDACs is 
achieved by DREAM. Notably, Chromatin Immunoprecipitation (ChIP) 
assay demonstrated that HDAC4 and HDAC5 binding on ncx3 promoter 
was significantly increased after transient middle cerebral artery occlusion 
(tMCAO).  
Our findings identify a new epigenetic regulatory mechanism that controls 
NCX3 gene transcription and demonstrated that HDAC class II A 
inhibition, by blocking HDAC4 and HDAC5 and modulating the acetylation 
of ncx3 gene promoter sequence, could be a new therapeutic strategy in 
stroke treatment. 
  
 
 
 
 
 
 
Introduction 
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I. INTRODUCTION 
I.A. PATHOPHYSIOLOGY OF CEREBRAL ISCHEMIA 
Stroke has been described into two main forms: ischemic and 
hemorrhagic, however the ischemic form is more common than the 
hemorrhagic. Several drug trials have been directed to find a cure for the 
ischemic form since the ischemic event represents about the 87% of all 
the cases of stroke. 
Ischemic stroke can be caused by a reduction in the brain blood flow as 
consequence of a thrombosis, an embolism or a systemic hypo-perfusion. 
Within the ischemic core, where the oxygen and glucose reduction 
delivered by blood vessels is seriously restricted, excitotoxic and necrotic 
cell death occurs within minutes, whereas in the peripheral ischemic area, 
the collateral blood flow can buffer injury, leading to different outcome [1].  
 
I.A.1. Excitotoxicity and ionic imbalance  
In a resting neuron the cytoplasmic concentration of free Ca2+ is 
approximately around 100 nM, whereas at the extracellular side is 
estimated to be concentrated 1-2 mM. The intracellular ionic homeostasis 
of Ca2+ is regulated by several mechanisms including specific activation of: 
receptors, channels, and ionic pumps. The entry of extracellular Ca2+ is 
mediated by the activation of ligand-operated receptors and voltage-gated 
Ca2+ channels. The release of Ca2+ from inner stores such as the 
endoplasmic reticulum is allowed by the stimulation of inositol triphosphate 
(IP3) receptors and Na+ -Ca2+ exchanger activation. The extrusion of Ca2+ 
from the cell requires an active transport mediated by the Ca2+-ATPase or 
Na+ -Ca2+ exchanger in the plasma membrane. Furthermore, the 
intracellular Ca2+ buffering is regulated by specific target proteins that bind 
free Ca2+ causing a decrease in cytoplasmic free levels as well as by the 
sequestration of Ca2+ into the endoplasmic reticulum through Ca2+-
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ATPase or through mitochondria uniport mechanism activation [2,3,4,5]. 
Thus, energy failure in hypoxic ischemia will cause the accumulation of 
intraneuronal free Ca2+ (Ca2+ overload) by enhancing the entry and 
releasing from the stores, and by interfering with the ATP-dependent 
extrusion and sequestration of this ion. 
Blood flow interruption in the brain causes deprivation of oxygen and 
glucose that are used as energetic substrates. Furthermore, impairment in 
energy production increases glutamate release via membrane 
depolarization and subsequent voltage gated Ca2+ channels activation. It 
also interferes with the re-uptake of glutamate (primarily into astrocytes), 
leading to its abnormal accumulation into synapses [2]. After ischemia, the 
energetic depletion decreases the function of Na+/K+-ATPase and Ca2+-
ATPase, which are important plasma membrane ionic pumps found in 
neurons. A failure in energy production induces membrane depolarization, 
release of potassium into the extracellular space and entry of sodium and 
calcium into the cells [6]. The membrane depolarization is also responsible 
for the activation of the N-methyl-D-aspartate receptors (NMDA receptors). 
The heteromeric NMDA receptors are highly permeable to Ca2+, as well as 
Na+ and K+. NMDA receptors can be fully activated under plasma 
membrane depolarization thus abolishing its Mg2+ - induced inhibition. 
Since a brief (>3 min) activation of NMDA receptors is sufficient to trigger 
neuronal death, the activation of NMDA receptors has been proposed as a 
primary cause of neuronal death after the focal cerebral ischemia that is 
accompanied by the transient (~30- 60 min) elevation of extracellular 
glutamate [7,8]. The Ca2+ influx through NMDA receptors mediates the 
rapidly-triggered NMDA neurotoxicity, while Na+ influx contributes to the 
swelling of the neuronal cell body [9]. The entry of Ca2+ via NMDA 
receptors activation contributes further to the Ca2+ overload following 
hypoxic-ischemic injury, in fact NMDA antagonists prevent the entry and 
accumulation of Ca2+ in neurons exposed to oxygen and glucose 
deprivation (OGD), an hypoxic-ischemic condition in vitro [10,11]. 
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Prolonged increases in intracellular Ca2+ levels lead to  catabolic 
processes and irreversible neuronal death in the ischemic core through 
multiple mechanisms that involve the activation of Ca2+- binding effector 
proteins such as calcium dependent proteases, lipases and DNAses [12]. 
 
I.A.2. Oxidative and nitrosative stress 
Oxidative stress has been strongly implicated in triggering both necrosis 
and apoptosis processes in case of focal ischemia, above all when 
followed by reperfusion [13,14]. In physiological conditions, mitochondria 
are the major producer of superoxide. As the ischemia occurs, 
mitochondria probably contribute to increase oxidative stress in ischemic 
and post-ischemic brain [15]. 
The increase of intracellular calcium, sodium and adenosine diphosphate 
(ADP) induces mitochondria to produce the deleterious reactive species of 
oxygen (ROS), which consequently leads to cellular macromolecules 
(mainly lipids and proteins) destruction. ROS are involved in the activation 
of signaling mechanisms resulting in apoptotic cell death [16]. Moreover, 
the high production of superoxide and nitric oxide (NO) affects protein 
structure and leads to peroxynitrate levels increases. Thrombolytic therapy 
is effective just during the 4,5 hours after the occurrence of stroke. The 
reason for this limited therapeutic window is found in the surge of 
production of free radicals during the delayed reperfusion phase. The 
oxygen that newly perfuses tissue is responsible for the second wave of 
oxidative and nitrosative stress that increases the risk of brain hemorrhage 
and edema.  
 
I.A.3. Apoptosis 
Emergent evidence suggests a role for caspases during neuronal death 
after brain ischemia [17]. The caspases are a family of proteases that 
include in their catalytic site the cysteine-containing pentapeptide motif 
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QACXG (X being R, Q or G) and share the feature of an aspartate residue 
at the N-terminal end of the substrate cleavage site [18,19,20,21,22]. 
There is an huge evidence that during ischemic injury caspases are 
activated in the brain. In fact, up-regulation and activation of caspase-3 
was found to precede neuronal death. 
In the rat brain during transient global ischemia, the activation of caspase-
3 induces the cleavage of inhibitor of caspase-activated 
deoxyribonuclease (ICAD), thus resulting in the apoptotic degradation of 
DNA by caspase-activated deoxyribonuclease (CAD) [23]. 
Deoxyribonuclease activity resulting from transient focal ischemia in the 
rat could be prevented by inhibitors of caspase-3-like activity [24]. 
Focal brain ischemia was reported to increase levels of mRNA and protein 
of several procaspases, including -3, -6, and -8 [25,26,27], and to cause 
activation of caspases-3 [27] and -8. The activation of caspase-8 that has 
been documented in a few studies of experimental brain ischemia [27, 28] 
suggests that receptor-mediated activation of caspases could contribute to 
ischemic brain damage. The release of tumor necrosis factor alpha (TNF-
α), by ischemic neurons, glia, activated microglia and infiltrating 
inflammatory cells could stimulates many receptors linked to caspases 
[29,30,31]. The mitochondrial pathway of programmed cell death involves 
the release of cytochrome c, procaspase-9, and apoptotic protease 
activating factor 1 (Apaf-1) from the mitochondrial intermembrane space 
and a series of subsequent biochemical interactions that include the 
activation of caspase-9 and lead to the activation of caspase-3. 
Mitochondrial release of cytochrome c after brain ischemia is caused by 
the action of Bax (bcl-2-like protein 4) and other pro-apoptotic members of 
the B-cell lymphoma 2 (Bcl-2) family [32,21,33]. The death of neurons 
after brain ischemia is preceded by an increase in the level of Bax 
[34,35,36,37,38,39]. After transient focal brain ischemia, Bax translocates 
rapidly from the cytosol to the mitochondria, where it interacts with the 
mitochondrial adenine nucleotide translocator and the voltage-dependent 
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anion channel. The timing and regional distribution of the translocation of 
Bax coincides with the mitochondrial release of cytochrome c and 
caspase-9. 
 
I.A.4. Inflammation 
Inflammation plays an important role in the pathogenesis of ischemic 
stroke and other forms of ischemic brain injury [40]. Among the various 
types of leukocytes, neutrophils are the first to infiltrate ischemic brain (30 
min to a few hours after focal cerebral ischemia). Infiltrating neutrophils 
release several pro-inflammatory mediators stored in granules and 
vescicles, such as inducible nitric oxide synthase (iNOS) and matrix 
metalloproteinases (MMPs) [41], thus triggering inflammation and injury. 
Microglia could be rapidly activated within few  minutes in response to 
cerebral ischemia [42,43]. The inflammatory mediators released from the 
activated microglia lead to cell damage and death. 
By contrast, microglia can also produces the transforming growth factor β1 
(TGF-β1), which acts as a neuroprotective molecule [42]. These dual and 
opposite functions may be referred to the different activation time of 
microglia since data suggested that early activation is detrimental and later 
activation is beneficial [44]. 
After ischemic stroke, astrocytes proliferate and differentiate, a condition 
known as astrogliosis. Also the astrocytes release several inflammatory 
mediators [45,46] such as TNF-α, a potent pro-inflammatory cytokine, that 
was found  upregulated in the brain after both permanent [47] and 
transient middle cerebral occlusion (pMCAO and tMCAO) [48]. 
Matrix Metalloproteinase (MMPs), a family of zinc-dependent proteolytic 
enzymes, are normally as a pro- or inactivated forms and can be activated 
by the removal of amino-terminal pro-peptides. Their constitutive 
expression is low, but can be upregulated by many pathogenic events, 
including stroke. MMPs play important roles in brain injury after stroke. 
Among various MMPs, MMP-9 is most closely implicated in cerebral 
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ischemia [49]. MMP-9 was upregulated in brain tissue and also in serum of 
patients with acute ischemic stroke [50]. It was associated with blood brain 
barrier (BBB) disruption, edema development, and hemorrhagic 
transformation of ischemic stroke [51,52]. 
 
 
I.B. EPIGENETICS 
 
Epigenetics is a branch of molecular biology that investigates heritable 
changes in genic expression without alterations in the original DNA 
sequence. Among the various epigenetic modifications, three major 
categories have been described such as DNA methylation, histone 
posttranslational modifications, and noncoding RNAs (ncRNAs) which 
include microRNAs (miRNA), small noncoding RNAs (sncRNA), and long 
noncoding RNAs (lncRNA) [53].  
 
I.B.1. Nucleosome 
Chromatin is the complex of DNA wrapped around histonic proteins found 
in the  eukaryotic nuclei. The functional unit of chromatin, the nucleosome, 
represents the primitive structure allowing the packing of all the entire 
genome (Figure 1-A). Each nucleosome is composed of an octamer of 
histonic proteins and consists of two copies of each histones (H2A, H2B, 
H3 and H4) wrapping a segment of 147 base pairs long DNA [54]. 
Histones, enriched in basic amino acids, are proteins which structure is 
made of a globular domain and an N- terminal tail protruding from the 
nucleosome. Although the histones are classified among the most 
evolutionarily conserved proteins, they represent the most variable in 
terms of posttranslational modifications.  
The N- terminal tails of histones are usually targets for various covalent 
posttranslational modifications, including acetylation, phosphorylation, 
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methylation, sumoylation and ubiquitination (Figure 1-B). The specific 
combinations in posttranslational  modifications generate a sort of “histone 
code”. The role of these modifications is found in their particular 
combinatorial pattern since they decode for a selective chromatin affinity 
to the associated proteins, which determine whether the chromatin is 
active (relaxed state) or silent (condensed state) [55]. Thus, histone code 
influences the structure and pattern of chromatin condensation and 
consequently it has been found involved in the gene regulation [56].  
 
 
Figure 1.  Chromatine organization into nucleosomes (A) and epigenetic modifications (B).  
 
I.B.2. Epigenetic modifications 
The histone tail modifications are likely to act in concert with the rather 
more widely known mediator of chromatin structure and gene expression, 
namely DNA methylation that happens through the action of DNA 
methyltransferases (DNMT) (Figure 1-A).   
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DNA methylation is an important regulatory mechanism of gene 
expression in eukaryotes. In mammals and humans DNA methylation 
mostly affects the cytosine (C) base when it is followed by a guanine (G). 
These CpG sites can be clustered in the so-called “CpG islands” (GCI) but 
DNA methylation can also be present in non-CG contexts [57]. This 
modification is known to have a role in the constitutive silencing of 
chromatin regions, the inactivation of one of the X chromosomes in 
females, the imprinting of parental alleles, and the silencing of retroviral 
genes and other individual genes [58]. In addition to DNA methylation, 
also histone posttranslational modifications act on the chromatin 
conformation. In fact, methylation and especially trimethylation of histone 3 
(H3) at lysine site 27 (H3K27me3)/lysine 9 (H3K9me3) induces  gene 
repression. Conversely, methylation of H3K4 normally indicates active 
enhancers [59,60]. Hundreds of histone modifications have been found 
affecting histones into many different residues including  lysine (K), 
arginine (R), serine (S), threonine (T), and glutamate (E) [61]. 
Recent studies explored in more detail the complexity of information 
brought from the epigenetic modifications on histone tails. Currently, there 
are 50 different acetylated isoforms of the histones forming the 
nucleosome core, with a total of 16 different isoforms for  H2B, H3, and H4 
and only two for H2A. In addition, these isoforms have been found further 
modified via methylation on specific lysines and arginines sites (H3 and 
H4) and via phosphorylation on serine (H3, H4, H2B) [62].  
The total combination of the possible histone isoforms carrying the various 
modifications may give rise to a thousands possible patterns. Recent 
evidence explored the role of specific proteins which are recruited to 
particular post translational modifications (PTMs) on histones, thus 
sheding light to the so called “histone code hypothesis” [63]. Certain PTMs 
form a docking platform for the recruitment of subsequently acting histone 
modifiers that associate with the “readers” of these PTMs.  
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I.B.3. Acetylation and deacetylation  
Among the histone modifications, acetylation and deacetylation of specific 
residues of histone tails have been described having opposing effects on 
the chromatin activation. The activity of two principal classes of enzymes, 
the histone acetyltransferases (HATs) and histone deacetylases (HDACs), 
determines transcriptional activation state of a specific region in the 
genome. HATs acetylate the ε-groups of the lysine residues of the histone 
tails, whereas the acetyl groups removal, HDACs-mediated, restores 
positive charge on these residues. Consistently, active transcriptional 
regions of the chromatin generally associate with highly acetylated 
histones H3 and H4 in euchromatic regions of the genome [64]. Histone 
acetylation plays an important role in chromatin remodelling, affecting on 
the modulation of transcription [65,66]. In fact, the recruitment of HATs by 
transcription factors to specific genetic loci determines the grade of local 
acetylation of histones. Importantly, HATs work as integration hub in many 
various signaling cascade since they can interact with a large number of 
transcription factors [67]. Conversely, the histone deacetylation activity, via 
HDACs, removes acetyl moieties, serving as inactivating signal for 
chromatinic transcription. HDACs inhibition restores the grade of  histone 
acetylation, chromatin relaxation and gene expression. The imbalance 
between the activity of HATs and HDACs generally associates with the 
development of a pathophysiological state. Moreover, HATs and HDACs 
activity can also target non-histonic substrates such as the tubulin and 
transcription factors including the tumor suppressor p53, specificity protein 
1 (Sp1), Sma-Mothers against decapentaplegic homolog 7 (Smad7), 
cAMP response element-binding protein (CREB), the pleiotropic 
transcription factor nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB), and signal transducer and activator of transcription 1 
(STAT1) [68].  
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I.B.4. Histone Acetyltransferase (HAT) Families 
Histone acetyltransferases (HATs) catalyze the reaction of histones 
acetylation through addition of an acetyl group of the pseudo-substrate 
acetyl coenzyme A (acetylCoA) to the lysine residue on the ε-amino group 
on the N terminal side of histonic core. HATs may act also on non-histone 
proteic substrates, requiring a new specific nomenclature for these 
enzymes. For instance, “HATs” that acetylates lysine (K) residues should 
be referred to as KAT (lysine acetyl transferase) [69]. The family of HATs 
is found evolutionary well conserved from yeasts to humans.  
The most common HATs are classified as cytoplasmic (type A) and 
nuclear (type B). Nuclear HATs are further grouped into 5 major classes: 
1) Gcn5- related N-acetyltransferases (GNAT), 2) p300/cyclic adenosine 
monophosphate response element-binding protein (CREB) binding protein 
(CBP), 3) MOZ, yeast YBF2, SAS2, and TIP60 (MYST), 4) transcription 
factor-related HATs, and 5) nuclear receptor-associated HATs such as  
TATA-binding protein (TBP)-associated factor (such as TAF130/150) [70]. 
Most of these histone acetyltransferases show a tipical regulatory function 
in transcription. The TAF130/250 histone acetylase [71] is a subunit of the 
Transcription Factor II D (TFIID) complex, a basic component of the 
Polimerase II (Pol II) transcription machinery in all eukaryotic organisms; it 
is likely to be associated essentially with all promoters during 
transcriptional initiation. The p300/CBP histone acetylase [72,73] was 
described initially as a transcriptional coactivator that functions by 
interacting with a wide variety of enhancer-binding proteins [74]. However, 
p300/CBP is tightly associated with the Pol II holoenzyme [75], suggesting 
the possibility that this histone acetylase could be viewed as a more 
general component of the transcription machinery. p300/CBP is found in a 
variety of multicellular organisms from worms to humans, but it does not 
exist in yeast [76]. 
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I.B.5. Histone Deacetylases (HDACs): Structure–Function Analysis 
Two families of histone deacetylases have been described in eukaryotes: 
the histone deacetylases (HDACs), and the Sir2-like deacetylases 
(sirtuins).  
The HDAC enzymes possess an highly conserved domain, consisting in 
approximately 390 amino acids, which appears to deacetylate substrates 
by activation of a water molecule with a divalent zinc cation coupled to a 
histidine-aspartate exchange system [77]. The HDAC family members can 
be classified  into two classes according to their similarity to yeast histone 
deacetylases Rpd3 (reduced potassium dependency 3) for the class I, and 
Hda1 (Histone deacetylase-A) for the class II [78] (Figure 2). HDAC 11 is 
the unique member of class IV HDAC since it does not share the 
characteristics of Rpd3 (class I) and Hda1 (class II) histone deacetylases.  
Four class I (HDAC1, 2, 3, and 8) and five class II (HDAC 4, 5, 6, 7, and 9) 
HDACs have been identified and partially characterized in humans  
[79,80], and there are potentially more deacetylases in this family 
according to the genome sequence [81]. Recently, a second family of 
histone deacetylases, the sirtuins, was identified. This group of proteins is 
related to the yeast transcriptional repressor Sir2, and its members can be 
divided into five classes based on their primary structure [82]. The sirtuin 
deacetylases contain a conserved 275 amino acid catalytic domain, which 
is unrelated to that of the HDACs, and the sirtuins operate by a very 
different mechanism that requires nicotinamide adenine dinucleotide 
(NAD) as a substrate. Despite these structural and mechanistic 
differences, proteins from both families have been shown to silence 
transcription at specific promoters or chromosomal domains by localized 
histone deacetylation. However, it is likely that members of the two 
families function in other cellular processes with non-histone substrates 
[83].  
 
 
13 
 
 
I.B.5.1. HDAC family members 
HDAC1 was the first histone deacetylase to be identified and 
characterized. Sequence analysis of HDAC1 revealed the homology of the 
human form with yeast protein Rpd3, showing a regulatory transcriptional 
function. Subsequent fractionation of the histone deacetylase activity in 
yeast yielded at least two distinct protein complexes, one of which 
contained Rpd3, and the other of which contained a highly related protein, 
Hda1. Hda1 contains the conserved HDAC catalytic domain and 
possesses deacetylase activity, but it is significantly larger in size than 
Rpd3. Human HDACs group consist in eight cloned proteins classified 
according their structure and size into the class I, having homology to 
Rpd3 (HDAC1, 2, 3, and 8), and the class II, with greater similarity to Hda1 
(HDAC4, 5, 6, 7, and 9) [84]. All of these proteins share a conserved 
catalytic domain and in vitro histone deacetylase activity. Class II HDACs 
appears two to three times larger in size than the class I proteins. Class II 
HDACs protein are further subdivided into two main groups. Class IIa 
HDACs consist of four members (HDAC4, HDAC5, HDAC7 and HDAC9) 
with distinct tissue specific patterns of expression, predominantly in 
muscle and heart [85].  Class IIb HDACs include HDAC6 and HDAC10. 
The structure of HDAC6 is unusual in that it contains two independently 
functioning catalytic domains and a carboxy-terminal Zn2+-finger ubiquitin 
binding domain. HDAC6 functions in the cytoplasm where it deacetylates 
α-tubulin and alters microtubule stability [86,87]. Its close structural 
homologue HDAC10 lacks the second functional catalytic domain [88]. 
HDAC10 has been found in a complex with HDAC3, although the exact 
functions of this deacetylase are still unknown. 
HDAC1 and HDAC2 are the best characterized among the HDAC proteins 
generally found in stable, multicomponent complexes of proteins, which 
are then recruited by DNA binding proteins. Three complexes containing 
HDAC1 and HDAC2 have been characterized thus far: the Sin3, the NuRD 
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(Nucleosome Remodeling Deacetylase), and CoREST (REST 
Corepressor 1) complexes [83]. The Sin3 complex includes a central core 
composed of SAP18 (Sin3A-associated protein of 18 KDa) and SAP30 
(Sin3A-associated protein of 30 KDa) proteins, and mSin3A, which 
stabilizes the complex serving as scaffold structure for various DNA 
binding proteins [89]. The NuRD complex also contains a core complex of 
MTA2 (Metastasis-associated protein 2), which is related to protein MTA1 
(Metastasis-associated protein 1) and CHD3 (Chromodomain-helicase-
DNA-binding protein 3)  and CHD4 (Chromodomain-helicase-DNA-binding 
protein 4) also called Mi-2α and Mi-2β respectively, which possess DNA 
helicase/ATPase domains found in the SWI/SNF (SWItch/Sucrose Non-
Fermentable) family of chromatin remodeling proteins [90].  
The CoREST complex includes HDAC1 and HDAC2 but not RbAp46 (Rb-
associated protein 46) or RbAp48 (Rb-associated protein 48). Another 
member of this complex is p110 [78]. 
HDAC4 and HDAC5 associate with HDAC3 [78] to form a complex with  
N–CoR (nuclear receptor corepressor) and SMRT(silencing mediator for 
retinoid and thyroid receptors)  [91]. Interaction of HDAC4 or HDAC5 with 
14-3-3 proteins has been discovered as sequester mechanism of the 
protein into the cytoplasm. When they dissociate HDAC-4 and HDAC-5 
translocate to the nucleus where they bind HDAC-3  and repress gene 
expression [92,93]. 
 
I.B.5.2. Sirtuin Family Members   
The third family of histone deacetylases, sirtuins, are homologues of the 
yeast Sir2 gene, which function is related to chromatin silencing, cellular 
metabolism, and aging [94]. In humans have been described seven 
sirtuins, SIRT1-7, which sequences have a mean of 300-400 amino acids, 
except that for SIRT1 (747 amino acids). Sirtuins possess several 
conserved sequence motifs. The catalytic domain of about 275 amino 
acids consists of two sets of CXXC motifs, which may function as zinc 
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finger domains [95], and more hydrophobic regions that may function as 
leucine zippers [96]. Sirtuins deacetylase activity is dependent by the 
presence in the reaction of NAD+ [97], whereas yeast Sir2 possesses an 
intrinsic ADP-ribosyltransferase activity [95]. 
SIRT-1 deacetylates p53, repressing its activity of transcriptional promoter 
of anti-apoptotic genes in response to DNA damage [98,99-100,101].  
 
I.B.6. HDACs inhibitors 
HDACs inhibitors (HDACI) were developed initially like molecules of 
oncologic interest because of their anticancer potential. Subsequently, the 
spectrum of therapeutic applications of these drugs was extended also to 
other human pathologies such as central nervous system diseases, on the 
basis of promising in vivo applications to polyglutamine-repeat diseases. 
Great efforts have been made to develop other compounds with 
characteristics similar to already known HDACI, in order to treat brain 
disorders [102]. HDAC inhibitors such as trichostatin A (TSA) and 
suberoylanilide hydroxamic acid (vorinostat, also known as SAHA), inhibit 
all zinc-dependent HDACs and for this reason are called pan-HDACI 
(Figure 2). These molecules cross the blood–brain barrier (BBB) and 
share the mechanism of action, committed to their hydroxamate moiety 
that is able to bind the zinc ion at the HDAC active site to inactivate the 
enzyme. Sodium butyrate and 4-phenylbutyrate are fatty acid derivatives 
that inhibit most class I and II HDACs, except HDAC-6. Valproic acid is 
another HDACI that not only is capable to cross the BBB but possesses 
also anticonvulsant properties, in particular this molecule inhibits class I 
and class IIa HDACs, but not class IIb [103].  
MC1568 selectively inhibits the HDAC class IIa. MS-275 is a synthetic 
benzamide derivative that preferentially inhibits HDAC1, compared with 
HDAC2, 3 and 9, and has little or no activity against HDAC4, 6, 7, and 8. 
This drug also passes the BBB easily and appears to produce no severe 
side effects. Apicidin, a cyclic tetrapeptide, inhibits HDAC2 and 3 in the 
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low nanomolar range and HDAC8 in the high nanomolar range, but does 
not affect HDAC1 or class II HDAC [104]. Romidepsin (FK-228), another 
cyclic tetrapeptide, also potently inhibits HDAC1 and 2 [105]. Tubacin is a 
catalytic domain-targeting small molecule inhibitor showing high selectivity 
for HDAC6 and for the deacetylation of α-tubulin, a microtubule 
component [106]. Nicotinamide, also known as niacinamide, is a precursor 
of NAD+ and a competitive class III HDAC inhibitor that can be given orally 
[107]. 
 
 
 
Figure 2. Classification of HDACs and HDACI. Jessica E. Bolden, Melissa J. Peart and Ricky W. 
Johnstone Nature Reviews Drug Discovery 5, 769-784 (September 2006). 
 
 
I.B.7. Neuroprotection by HDAC Inhibition in Cellular Models 
HDAC inhibition exerts a neuroprotective effect in both in vivo and in vitro 
models of brain disorders. Pioneering study support that levels of the 
HATs CBP/p300 and histone proteins acetylation were decreased during 
MC1568
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apoptosis induced by potassium deprivation of cultured primary cerebellar 
granule cells, and during signaling activation of β-amyloid precursor 
protein (APP) in cultured primary cerebral cortical neurons from rodents 
[108]. Moreover, overexpression of CBP/p300 protected these neurons 
from proapoptotic insults. In cortical neurons, Ryu and colleagues showed 
that treatment with TSA, sodium butyrate, or vorinostat protected against 
glutathione depletion-induced oxidative stress; neuroprotection involved 
the acetylation and subsequent activation of the DNA binding activity of 
Sp1 [109]. However, it is well known that some HDAC inhibitors, such as 
TSA, have basal toxicity and prolonged treatment at high doses often 
induces neuronal death, so compromising their neuroprotective effects 
[110]. HDAC inhibitor-induced neurotoxicity could be partly due to 
‘derepression’ of genes involved in apoptosis including Bim and B-myb 
[111]. In fact, Langley and colleagues found that a two-hour pulse 
treatment with TSA sufficed to rescue cortical neurons from oxidative 
stress without obvious toxicity; protection was associated with 
transcriptional activation of the cell-cycle inhibitor p21waf1/cip [112]. 
Glutamate-induced excitotoxicity has been implicated in the 
pathophysiology of many neurodegenerative and neuropsychiatric 
diseases; these include stroke, Huntington’s disease, amyotrophic lateral 
sclerosis, spinal cord and traumatic brain injury, cerebellar degeneration 
and possibly Alzheimer’s disease, Parkinson’s disease and mood 
disorders. Notably, Leng and Chuang demonstrated that valproic acid, 4-
phenylbutyrate, or TSA treatment protected against glutamate-induced 
excitotoxicity in brain, with concomitant transcriptional activation and 
induction of α-synuclein, a presynaptic protein of unknown function. 
Recent experiments demonstrate that overexpression of endogenous α-
synuclein plays a neuroprotective role; this appears to involve upregulation 
of the cytoprotective protein B-cell lymphoma 2 (Bcl-2) but downregulation 
of Ube2n (Ubiquitin conjugating enzyme E2 N), a proapoptotic, ubiquitin-
conjugating enzyme. A subsequent study showed that α-synuclein 
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protected cerebellar granule cells from 6-dihydroxydopamine-induced 
death. It appears that α-synuclein is neuroprotective in the cytoplasm, but 
becomes neurotoxic once translocated to the nucleus, where it inhibits 
HAT activity [113,114, 115]. A more recent study found that valproic acid 
and other class I and II HDAC inhibitors (e.g. sodium butyrate, 4-
phenylbutyrate, and TSA) potentiated these neuroprotective effects 
against excitotoxicity, when used in conjunction with lithium, another mood 
stabilizer with a robust neuroprotective profile [116]. Taken together, these 
findings suggest that HDAC inhibitors induce the expression of multiple 
downstream targets that might work collectively to elicit neuroprotective 
effects. Furthermore, HDAC inhibitors increase the expression of 
neurotrophins, molecules that play prominent roles in neuronal 
development, synaptic plasticity, and neuronal survival. For instance, 
Yasuda et al. found that brain-derived neurotrophic factor (BDNF) was 
induced in rat cortical neurons by treatment with valproic acid, sodium 
butyrate or TSA [117]. Hong and colleagues found that both BDNF and 
glial cell line-derived neurotrophic factor (GDNF) were induced by class I 
and II inhibitors in primary cultures of astrocytes from rat midbrain [118, 
119, 120]. Considerable previous studies have reported that HDAC 
inhibitors exerted neuroprotective effects by preventing microglia 
activation, and anti-neuroinflammatory effects in some central nervous 
system (CNS) diseases [121]. The anti-inflammatory effects of HDAC 
inhibitors were also found in an animal model of cerebral ischemia. Taken 
together, the in vitro studies demonstrate that HDAC inhibitors exert their 
neuroprotective effects through multiple mechanisms and that, in addition 
to neurons, glia is also target of HDAC inhibition and neuroprotection 
[122]. 
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I.B.7.1. Huntington’s Disease (HD) 
The role of HDACs in neurodegenerative disorders was primarily 
discovered through experiments showing that HDAC inhibitors were able 
to improve the cognitive and motor deficits characteristic of Huntington’s 
disease (HD). HD is a neurodegenerative disorder with autosomal-
dominant inheritage. The late onset of this disease accompanies with 
progressive motor, psychiatric and cognitive decline. A typical feature of 
this disease is a massive death in cortical and striatal neurons which 
cause is thought to be in the polyglutamine (CAG) expansion in the 5’ 
coding region of the huntingtin (htt) gene [123, 124]. 
Mutant huntingtin accumulates in the nucleus where its aggregates in 
polyQ proteins bind many different transcription factors and coactivators 
such as CBP [123, 124], thus mutant huntingtin is thought be responsible 
for transcriptional dysregulation. In fact, a lower CBP availability leads to 
dysregulation in CBP/CREB - mediated gene expression, histone 
deacetylation and neuronal loss. Early studies demonstrated the ability of 
HDAC inhibitors to rescue lethality and photoreceptor neurodegeneration 
in a Drosophila model of polyglutamine disease [125]. These findings were 
extended to the mouse models of HD by several laboratories, who showed 
that treatment with HDAC inhibitors such as sodium butyrate and 
phenylbutyrate attenuate neuronal loss, increase motor function and 
extend survival in R6/2 mice [126, 127]. 
These findings strengthen the idea that epigenetic dysregulation plays a 
critical role in the pathogenesis of HD further suggesting the efficacy of 
therapeutics as cure for the alterations in epigenetic modifications, since 
they have also beneficial effects after the onset of the disease [67]. 
 
I.B.7.2. Parkinson’s disease 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that 
affects 1% of the population over 65 [128]. 
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Although the etiology of PD is not well defined, familiar PD cases share a 
lack of nuclear α-synuclein. Recent studies explored the role of HDAC 
inhibitors as therapeutics of this progressive neurodegenerative disease. 
The initial link between PD and epigenetic dysregulation came from 
studies on Drosophila. Using a Drosophila model of PD, Feany and 
colleagues demonstrated that nuclear targeting of α-synuclein promotes its 
toxicity and that sequestration of α-synuclein to the cytoplasm is protective 
[113]. It was further shown that α- synuclein binds directly to histones, 
reduces levels of acetylated histone H3 and inhibits HAT mediated 
acetyltransferase activity [113]. One study reported that nuclear α-
synuclein binds histones to inactivate HATs including CBP, p300 and 
P/CAF, causing histone hypoacetylation and apoptosis in human 
neuroblastoma cells. These findings implicate α-synuclein in the 
degeneration associated with PD. Administration of HDAC inhibitors in 
vivo or in vitro rescued α-synuclein- induced toxicity [113]. These findings 
underline the potential of HDAC inhibitors for therapeutic intervention in 
the neurodegeneration and cognitive impairments in PD. Future studies 
are needed to examine the efficacy of HDAC inhibitors in animal models 
for PD [67].  
 
I.B.7.3. Alzheimer’s disease  
Alzheimer’s disease (AD) is the fourth most common cause of mortality in 
the USA, affecting approximately the 50% of people over their eighties in 
industrialized countries. The clinical onset is characterized by progressive 
memory and mood changes, ultimately leading to dementia. The typical 
hallmark of the disease is the accumulation of the extracellular β-amyloid 
(Aβ) in the brain, and hyperphosphorylation of Tau protein. Toxic Aβ 
peptides derivate by the aberrant double cleavage of the APP (amiloid 
precursor protein) which normal processing produces physiological and 
non toxic substrates. Tau protein is an important protein involved in the 
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stabilization of microtubules structure, whereas its phosphorylation 
induces disassembling of cytoskeleton filaments.  
A follow-up study by Guan et al. elegantly demonstrated that mice 
overexpressing HDAC2, but not HDAC1, exhibited decreased dendritic 
spine density, a decreased synaptic number, a reduced synaptic plasticity, 
and impaired memory formation [129]. Conversely, Hdac2 knockout mice 
show memory improvement. Further, HDAC2 is involved in the regulation 
of hippocampal mouse synaptic formation and in neuronal plasticity by 
exerting its deacetylase activity on several promoter genes related to 
neuronal activity, synaptic formation and plasticity.  
The memory impairment showed by HDAC2 overexpressing mice was 
prevented via administration of the HDAC inhibitor vorinostat. These 
findings shed light on the role of chromatin modifications caused by  
HDAC2 in neuronal mechanisms of synaptic plasticity and memory 
formation. Experiments performed on animal models of AD such as 
Tg2576 mice, consistently demonstrated that in these animals daily 
injections of 4-phenylbutyrate reversed spatial memory deficits via 
normalization of hippocampal tau phosphorylation level, without affecting 
Aβ levels [130]; whereas on APP23 mice a daily administration of low 
dose of valproic acid (30 mg/kg, i.p.) significantly reduced Aβ plaques 
formation, and this effect was highly visible by administrating the drug 
during the early mouse life (seven months as minimum) [131].  
Nicotinamide administration induced chronic but slight increase in 
endogenous p25, leading to improvement in learning and memory skills. 
Although nicotinamide possesses a class III HDAC inhibitor effect, it has 
been demonstrated that it has both sirtuin-dependent and -independent 
functions. These findings suggest a therapeutic beneficial role of 
nicotinamide via oral administration as medical treatment for this disease.  
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I.B.7.4. Amyotrophic Lateral Sclerosis (ALS) 
The Amyotrophic Lateral Sclerosis (ALS) is a multifactorial disease where 
the motor neurons are injured. Among the multiple mechanisms that 
trigger neuronal death, alterations in genes transcription is crucial to 
perturb the cellular homeostasis, leading to the activation of many 
deleterious pathophysiological cascades. Recent findings demonstrate 
that the administration of sodium phenylbutyrate, an HDAC inhibitor, 
significantly extended survival and improved both clinical and 
neuropathological phenotypes in the G93A transgenic ALS mice model. 
Phenylbutyrate administration ameliorated histone hypoacetylation 
observed in G93A mice and induced expression of Nuclear Factor-kB (NF-
kB) p50, the phosphorylated inhibitory subunit of NF-KB (pIKB) and beta 
cell lymphoma 2 (bcl-2), but reduced cytochrome c and caspase 
expression. Moreover, curcumin, an NF-KB inhibitor, and mutation of the 
NF-KB responsive element in the bcl-2 promoter, were found able to block 
the butyrate-induced bcl-2 promoter activity. Several evidence 
demonstrated that the pharmacological induction of NF-KB dependent 
transcription and bcl-2 gene expression is neuroprotective in ALS mice by 
inhibiting programmed cell death. Phenylbutyrate phosphorylates IKB, 
allowing the translocation of NF-KB p50 to the nucleus, or acts directly on 
the acetylation of NF-KB p50. NF-KB p50 mediates the transactivation of 
bcl-2 gene expression which up-regulation blocks the cytochrome c 
release and the subsequent caspase activation, slowing motor neuron 
death. Several studies report that transcriptional and post-translational 
pathways ultimately promote motor neuron survival and ameliorate 
disease progression in ALS mice. According with these findings, it has 
been provided a possible role of phenylbutyrate as therapeutic approach 
for the treatment of patients with ALS [132]. 
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I.B.8. HDAC Inhibition in Animal Models of cerebral ischemia 
Stroke is the third cause of mortality in the United States and the first in 
terms of  disabilities in adults [133]. It displays an annual incidence of 
600,000 new victims which 30% remains severely disabled. Several stage 
III clinical trials failed and their inefficiency is mostly due to a limited time 
windows for medical first aid. In order to shed light to new neuroprotective 
strategies to rescue and repair the ischemic injury, new molecular 
mechanisms need to be discovered.  
In this field, modulation of translational mechanisms could be efficient 
subject of study among molecular strategies. Ischemic stroke could 
involve the whole brain (global ischemia) or just a limited area (focal 
ischemia). Global ischemia occurs in case of cerebral blood flow accidents 
such as cardiac arrest, surgery, hemorrhage and gaseous asphyxia via 
monoxide poisoning. Focal ischemia, instead, refers to localized 
cerebrovascular interruptions leading to selective damages. Hippocampal 
neurons in CA1 region are very sensible to the blood pressure decrease 
and their injury usually associates with severe cognitive disabilities.   
The substantial delay occurring between ischemic injury and neuronal 
death is consistent with a role for transcriptional changes. The 
transcriptional repressor RE1 silencing transcription factor REST (also 
named NRSF), widely expressed during the embryonic development, 
plays a crucial role in terminal neuronal differentiation [134, 135]. REST 
represses specific neural genes involved in synaptic plasticity such as 
vescicular proteins that play a pivotal role in trafficking mechanisms, 
structural proteins, voltage-gated channels and ligand-operated receptors 
[134,135]. REST activity is expressed both in neural progenitors that in 
non neural cells. During neuronal differentiation, REST orchestrates a 
large set of epigenetic modifications splitting up neuronal cells from non-
neuronal cells. Recent studies report that the high vulnerability of 
hippocampal neurons during a global ischemia strictly associates with 
anomalous accumulation of nuclear REST that  represses some 
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transcriptional mechanisms needed for the neural function [136]. In fact, 
REST represses specific target genes via binding of MeCP2 and other 
corepressor complexes that possesse Histone 3 Lysine 9 (H3K9) 
deacetylase and methylase functions. Recent findings proved further the 
role of REST on hippocampal selective neuronal loss via recruitment of 
CoREST, G9a and MeCP2 to the promoters of specific genes which 
epigenetic remodeling is cause of deleterious effects of the global 
ischemia [137]. The abnormal regulation of REST remodelling also affects 
a widespread number of others disorders such as the pathogenesis of the 
Down’s Syndrome, Alzheimer’s disease, Huntington’s disease, epilepsy 
and X-linked mental retardation [134, 135]. Two recent studies 
demonstrate the therapeutic role of HDAC inhibitors in the field of neuronal 
loss and cognitive decline in neurons injured by ischemia.  In fact, Chiarugi 
and collegues reported that intraperitoneal SAHA injection (HDAC 
inhibitor) in mice from 0 to 6 h after ischemic insult obtained through the 
middle cerebral artery occlusion (MCAO), was able to prevent H3 
deacetylation and promote the neuroprotective expression of Bcl-2 and 
Hsp70. Thus, the resulting reduction in volume infarct suggests a 
neuroprotective effect for SAHA [138]. Furthermore, Moskowitz, Dirnagl 
and collegues observed that the abnormal DNA methylation in mice 
subjected to ischemic MCAO model was prevented by administration of a 
combination of the demethylating agent 5-aza-2’-deoxycytidine and 
trichostatin A (HDAC inhibitor), conferring stroke protection. This effect 
was evident in mice subjected to mild but not to severe ischemic insult 
[139]. These findings highlight the potential therapeutic role of HDAC 
inhibitors in case of ischemic stroke as neuroprotective intervention [67].  
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I.C. SODIUM CALCIUM EXCHANGER  
 
The Na+/Ca2+ exchanger (NCX) is a nine transmembrane protein, 
distributed throughout the brain and the heart. NCX was primarily 
discovered and characterized in late 1960s from many independent 
laboratories: from Baker et al. in the UK [140, 141], also from Reuter and 
Seitz in Germany and Switzerland [142], and from Martin and De Luca in 
the United States [143].  
These laboratories individually discovered the presence of a 
countertransport mechanism that exchanged Na+ and Ca2+ ions across the 
plasma membrane of different excitable but also non excitable cells. In 
1988 and in 1990, Philipson and colleagues successfully performed the 
purification and cloning of the first isoform of NCX, the so-called NCX1, 
and some years later, the same investigation group cloned NCX2 [144] 
and NCX3 [145]. Among NCX isoforms, NCX2 and NCX3 are selectively 
expressed in the brain [146] and in the skeletal muscle [145]. The 
regulation of intracellular ionic concentrations of the previously mentioned 
cations, plays important roles in several cellular homeostasis mechanisms 
in excitable cells. In fact, sodium regulates cellular osmolarity, plays a 
crucial role in the induction of action potential [147], and also acts in 
transducing signaling pathways [148].  
Importantly, also calcium is involved in several cytosolic intracellular 
signaling mechanisms as second messenger. The sodium calcium 
exchanger works in association with other selective ionic channels and  
ATP-dependent pumps involved in the physiological mechanism of 
regulation of cytosolic ions concentrations [149]. NCX exchanges one Ca2+ 
ion with three Na+ ions in a bidirectional working manner (forward and 
reverse). The forward mode operates extruding one Ca2+ ion with the 
influx of three Na+ ions. This mechanism plays a crucial role in restoring 
intracellular Ca2+ levels as consequence of physiological rises of the 
cation. By contrast, in the reverse mode NCX carries out three Na+ and 
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one Ca2+ enters the cell. This operating mode is essential to re- equilibrate 
the Na+ concentration after membrane potential depolarization rises, thus 
reducing the transmembrane Na+ electrochemical gradient. The typical 
accepted stoichiometry 3:1 for NCX has been revisited in the last years. In 
addition to the major 3:1 stoichiometry, new ionic flux ratios from the 1:1 to 
a maximum of 4:1 are validated as functional working mode. The 
exchanging depends on the intracellular concentration of the two cations 
[150-151].  
 
I.C.1. State of Art of NCX1, NCX2 and NCX3 isoforms 
The knocking-out of NCX1 brings to embryonic lethality, whereas the 
overexpression of this exchanger isoform triggers heart dysfunction. To 
overcome these limitations and to shed light on neuroprotective role of 
NCX1, two conditional genetically modified mice have been generated. 
These animals, under tamoxifen administration, were able to decrease or 
increase NCX1 expression in neurons belonging to cortex and 
hippocampus, the two main regions involved in stroke. It has been 
demonstrated that the conditional overexpression of NCX1 in hippocampal 
and cortical neurons was able to trigger the phosphorylation of Akt [152], 
that elicits neuronal survival during brain ischemia. By constrast, the 
conditional knock-out of NCX1 in the same neuronal populations reduced 
the amount of phospho-Akt (p-Akt), leading to a  worsening ischemic brain 
damage [153].   
The neuroprotection exerted by the ischemic preconditioning is reached 
through different molecular effectors. It has been found that the isoforms 1 
and 3 of the Na+/Ca2+ exchanger play a crucial role in this protective 
mechanism. It has been demonstrated that the reduction of NCX1 
expression induced by ischemia was prevented when the animals were 
exposed preventively to preconditioning stimulus. After preconditioning 
plus tMCAO, NCX1 and NCX3 expression was markedly increased 
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compared to ischemic non preconditioned animals. Preconditioning 
triggers also the increase in the phosphorylation of Akt, further 
demonstrating the neuroprotective role of this protein related to NCX1 and 
NCX3 [154]. The neuroprotective preconditioning effects are dependent on 
several mechanisms, among these the activation of sensor molecules 
(such as hypoxia inducible factor-1 - HIF-1)  is crucial for neuroprotection. 
In particular, HIF-1 is a nuclear effector, which expression is induced by 
OGD or ischemic preconditioning and upregulates the transcription of 
NCX1 determining a neuroprotective effect in ischemic brain [155]. The 
regulation of NCX1 transcription has been widely investigated and it has 
been found that during tMCAO in rats Sp3 (specificity protein 3) and Re-1 
silencing transcription factor (REST) colocalize with HDAC1 and HDAC2 
on ncx1 promoter thus repressing NCX1 expression, whereas after 
preconditioning stimulus NCX1 transcription is elicited by the 
transcriptional activators Sp1 and HIF-1 forming a complex with histone 
acetyltransferase p300 on ncx1 promoter. Changes in NCX3 mRNA and 
protein expression were not associated with either the 
REST/Sp3/HDAC1/HDAC2 complex in tMCAO or the Sp1/HIF-1/p300 
complex in ischemic brain preconditioning [156]. Nowadays, the regulation 
of ncx3 promoter activity is not yet investigated during ischemia or after 
ischemic preconditioning. It has been demonstrated by Jeon et al. that 
NCX2 has also a neuroprotective role, in fact knockout mice for NCX2 
subjected to tMCAO displayed an increased neuronal loss with a 
consequential enlargement of infarct volume compared to wild-type 
animals. In a model of ischemia in vitro on hippocampal slices from ncx2-/- 
mice, it has been reported an increase of intracellular calcium level with 
membrane depolarization and slower recovery in population spike 
amplitudes compared to wild-type. These results indicate that NCX2 
working in forward mode plays a neuroprotective role, removing calcium 
from the cells during ischemia  [157].   
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I.C.2. Distribution of NCX isoforms in different tissues 
NCX1 is the most expressed protein of the SLC8 gene (solute carrier 
gene) family encoding for the Na+- Ca2+ exchangers. It was chiefly 
characterized and cloned as cardiac protein, then it has been disclosed in 
brain and kidney and minimally in other tissues [158–159]. NCX1 gene is 
alternatively spliced into two well-known sites giving tissue specificity [146, 
160]. 
The first site is located at the 5' untranslated region (5′ UTR) and does not 
alter the structure of the encoded protein. Otherwise, the presence of 
three different promoters independently drives the tissue specific 
expression for NCX, supposedly in response to different physiological 
requirements. [161,162]. 
The second site of splicing takes place into the coding region of NCX 
transcript, whereas two mutually exclusive and four cassette exons 
encode for a huge number of isoforms that differs just for the cytosolic 
inner portion of the exchanger [146,160,163]. 
The two mutually exclusive exons includes the exon A in the transcript of 
excitable cells, primarily muscular and nervous cells,  and the exon B in 
non-excitable cells. Nowadays, a combinatory pattern for cassette exons 
in tissues is not still available. Unlike NCX1, the other members of the 
SLC8 family show a more stringent tissue-specific expression pattern. In 
fact, NCX2 is present in neurons, but minimally in other sites and NCX3 
was found mainly expressed in the brain and skeletal muscle [164]. 
Recently, NCX3 has been detected also in the immune system and bones. 
Remarkably, NCX3, but not NCX2, is alternatively spliced and these 
spicing variants differ for the cytoplasmic region as it has already been 
demonstrated for NCX1. Since the three Na+ - Ca2+ exchangers, NCX1, 
NCX2 and NCX3 isoforms display a high homology of sequence, it is 
widely accepted that structure and the functional role of  NCX1 can be 
generally extended also to NCX2 and NCX3 isoforms [159-165]. 
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I.C.3. Molecular Biology of NCX3 
The cloning of the Na+- Ca2+ exchanger isoform 3 (NCX3) was achieved 
from rat at the Philipson’s laboratory in 1996 [145]. NCX3 displays 
approximately the 80% sequence homology with the other isoforms of the 
Na+-Ca2+ exchanger family NCX, including NCX1 and NCX2. The NCX 
structure expresses a different percentage of homology within the isoforms 
sequence. For istance, the 9 transmembrane domains share more than 
the 75% of homology within NCX1 and NCX2, but not the cytoplasmic f-
loop with just the 60%, thus suggesting that the transport mechanism 
requires the conservation of the transmembrane regions, whereas the 
NCX3 capacity is specifically restricted to the cytoplasmic loop. The exact 
structure of calcium-binding domain (CBD1) of NCX3 remains unknown. 
Nonetheless, the conservation of some key acidic and basic residues 
leads to the same Ca2+ binding sites and a structure most likely similar to 
NCX1. Therefore, the regulation of NCX3 capacity of exchange by CBD1 
is probably comparable to NCX1 [166]. The comparison of CBD2 has 
proven to be more difficult because of the alternative splicing of the NCX 
family causing various possibilities of sequence for CBD2. 
The NCX gene is spliced in different variants. It has been described more 
than 15 splicing variants for the isoform 1 and a exiguous number of 
variants for NCX3. NCX2 is the unique gene that does not present 
alternative splicing forms. NCX1 gene displays a tissue specific 
distribution [160,163;167]. The NCX3 gene is composed of 9 exons (exons 
from 1 to 9) [163]. Interestingly, exon 2 and 3– also named exon A and B, 
respectively - are mutually exclusive, whereas exon 4, named exon C, is 
optional. Thus, in the rat, three splice variants are detected. A variant 
containing exon A and C is found in skeletal muscle (NCX3-AC), while 
variants expressing the exon B are expressed in the brain (NCX3-B and 
NCX3-BC). Furthermore, in humans three truncated forms of NCX3 have 
been discovered of which two variants are expressed in the fetal brain 
(exons4- 9 and 6-9) [168]. The third truncated variant is expressed in 
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skeletal muscle (exons 2 and 6- 9) [169]. These human truncated forms 
are likely to be under the control of alternative promoters. Recently, the 
comparison of CBD2 deriving from NCX3-B and NCX1-AD exhibited a 
similar conformation in structures like the β-sandwich and the α-helix of 
the F-G loop [170]. The splicing variants of NCX1 display a various 
orientation in the α-helix which has been found associated with the 
activation or inhibition during the rise in intracellular calcium [Ca2+]I [171]. 
Conversely, the NCX3 helix found subsequently to the splicing region 
shows a unique orientation among the splicing variants, expressing an 
[Ca2+]i-dependent activation. NCX1 exons A and B have been found not 
only individually involved in the signal transmission to the transmembrane 
domains, but also in the mechanism to relieve the Na+-mediated 
inactivation [166]. The other NCX1 exons (C, D, E, and F) may regulate 
the Ca2+-binding affinity of CBD1 [172]. Overall, NCX3 splicing exons A, B 
and C are evolutionary well conserved among species, even a minor 
sequence homology compared with the NCX1 and NCX2 exons, which 
has been estimated approximatively around 55 and 65 %.Thus, it is quite 
impossible to apply the effect observed during the alternative splicing of 
NCX1 to NCX3. In addition, among the splicing variants, NCX3 exhibited 
different Ca2+ binding sites, which were identified three for NCX3-B and 
two for NCX3-AC. Interestingly, they expressed a different affinity for the 
Ca2+ [173]. 
According to the NCX structure, we can infer that differences among the 
axon A and B may have effect both on the Na+-dependent inactivation 
[166] and on the sensitivity to Ca2+ through changes in conformation of 
CBD1-CBD2. Finally, we can assume that in the last years important 
works elegantly investigated the mechanism of translocation in NCX and 
its regulation though CBD1 and CBD2 domains. Remains to reveal the 
mechanism that allows to the intracellular loop to influences the 
transmembrane segments and shed light on the role of the different 
alternatively splicing form of NCX3 [174]. 
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I.C.4. Identification of  NCX3 minimal promoter sequence 
In the 250 bp region immediately upstream of the exon 1 it has been 
identified the human SLC8A3 minimal promoter that displays similarities 
with SLC8A1 brain promoter. SLC8A3 minimal promoter includes in its 
sequence Sp1 and AP-2 (Activating Enhancer Binding Protein 2 Alpha) 
elements that are able to confer constitutive transcription and tissue 
specific expression, respectively. GC bases enrich both the sequences of 
SLC8A3 promoter and of exon 1, forming typical cytosine and guanine 
dinucleotide (CpG) island as it occurs at the 5' end of several 
housekeeping genes and oncogenes. The sequence of SLC8A3 promoter 
includes multiple AP-2 sites important for the regulation of physiological 
functions in nervous system, in fact members of the AP-2 transcription 
factor family are crucial for the vertebrate development of neuronal tube 
and neuronal crest derivatives. During mouse development, these 
transcription factors also differentiate in spatial and temporal expression 
[175]. The members of AP-2 family display an high tissue specific 
expression in neuroepithelium and neural crest [176]. Several consensus 
elements for AP-2 factors are present in promoters of peculiar neuronal 
genes such as choline acetyltransferase, proenkephalin; human fragile 
mental retardation promoter [FMR1], [177,178] as well as in other cellular 
types and genes (i.e., keratin, sodium-phosphate cotransporter [Npt2] of 
kidney proximal tubules and viral genomes as MMTV [179–180]). A single 
promoter region is required for the tissue-specific expression of the 
SLC8A3 gene, whereas the transcription of SLC8A1 gene depends from 
multiple tissue-specific promoters. SLC8A3 gene contains elements for the 
muscle-specific transcription factors MyoD (Myogenic Differentiation) and 
GATA factors 2/3; in agreement with the fact that the ortholog rodent gene 
is predominantly expressed in brain and skeletal muscles [145]. The 
SLC8A3 promoter has also consensus sequences for transcription factors 
AP1 (activating protein-1) , and Egr-1 (Early growth response protein 1 -  
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also known as NGF1-A, Krox24, Zif/268, or Tis 8). These are a subgroup 
of immediate early genes (IEGs) that are activated rapidly and transiently 
in neuronal cells in response to environmental stimuli, such as 
neurotransmitters and neurotrophin receptor stimulation, regulating the 
expression of subset of genes termed delayed-response genes. The 
dimerization of the Jun proteins (c-Jun; JunB and Jun D) and Fos proteins 
(c-Fos, FosB, Fra-1, etc.) through their leucine zipper motifs leads to the 
formation of AP-1 complex that binds to the consensus sequence 
TGACTCA. This sequence was first named as the element responsive to 
phorbol ester activation of protein kinase C (PKC). Jun proteins can also 
homodimerizes or heterodimerizes with Fos or with transcription factors of 
the ATF/CREB family. The composition of the AP1 complex can affect the 
affinity for consensus sequences and influence transactivation potential. 
Many different stimuli can regulate the transcription factors of the Egr 
family in mammalian brain, since they lack of bZip domain their binding to 
DNA can be achieved through zinc finger motifs. Egr-1 is induced rapidly 
after the activation of the NMDA receptor [181]. This increase of Egr-1- 
mRNA has been demonstrated in primary cultures of cerebellar, 
corticostriatal, cortical, and hippocampal neurons after stimulation by 
intraperitoneal administration of NMDA [182]. The MK-801, a blocker of 
NMDA receptors, downregulates the expression of Egr-1 [183]. The 
physiological synaptic activity can stimulate NMDA receptor and 
upregulates the Egr-1 expression, whereas kainate triggers the induction 
of all four members of the Egr family [184,185]. The link between Egr-1 
and SLC8A3 gene transcription is not yet clarified, however it seems that 
NMDA receptor activation triggers the upregulation of SLC8A3 
transcription. The physiological role of this functional link may be due to 
the role played by NCX3 in extruding calcium after NMDA receptor 
activation. A functional link between NMDA receptor and NCX3 is also 
suggested by their high expression in the hippocampus, especially in the 
CA1 region [182,164]. The SLC8A3 gene promoter contains the sequence 
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TGACGTGC identified like a CRE element [186, 187]. The CRE element is 
included in several other cAMP-responsive gene promoters, such as cfos, 
Zif/268, or Egr-1 and proenkefalin [188]. Calcium influx as well as cAMP 
triggers the activation of the c-fos gene through the CRE element that, for 
this reason, is called Ca2+ response element (CaRE). The presence of the 
CRE element has attracted much attention since it could confer rapid 
inducibility to the SLC8A3 gene, similar to that of IEGs. Several DRE 
elements are present in the SLC8A3 gene in the region downstream of the 
TATA box and in the exon 1; these sites are able to bind DREAM 
(downstream regulatory element antagonist modulator) [189,190,191-192].   
 
Figure 3. Regulation of ncx3 human gene transcription: role of DREAM and CREB. Gabellini 
N . Molecular Neurobiology, 2004.  
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I.D. PUTATIVE TRANSCRIPTION FACTORS REGULATING 
NCX3 AND THEIR ROLE IN NEUROPATHOLOGICAL 
CONDITIONS 
 
I.D.1. CREB 
In neurons, a wide range of extracellular stimuli activates signaling 
pathways like so CREB family members. Gene expression dependent by 
CREB pathway activation has been implicated in a complex and various 
series of processes ranging from development to plasticity, and eventually 
related also to diseases. CREB (cAMP response element binding protein) 
belongs to the bZIP superfamily of transcription factors. Within this 
superfamily, CREB and the closely related factors CREM (cAMP response 
element modulator) and ATF-1 (activating transcription factor 1) include a 
subcategory referred to as the CREB family. Belonging to the bZIP 
transcription factors, CREB family members contain a leucine zipper 
domain that facilitates CREB dimerization, and a C-terminal basic domain 
which role is binding with DNA. There is a high degree of homology 
among CREB, CREM, and ATF-1, allowing them to form both homo- and 
heterodimers, and each of these complexes takes place at the same side 
of cis-regulatory element as reviewed in De Cesare et al. 1999; Mayr and 
Montminy 2001 and Shaywitz and Greenberg 1999 [193, 194, 195]. The 
remaining domains of CREB family members mediate the interaction with 
coactivators and components of the transcriptional machinery to the DNA, 
facilitating RNA synthesis of genes having an important role in the nervous 
system. The most common CREB isoforms, CREBα and CREBΔ, display a 
kinase inducible domain (KID) between two domains enriched of 
glutamine residues, the so-called Q1 and Q2/CAD (constitutive active 
domain). The unique difference between these two activators is the 
presence of an α domain.  Following stimulation, the KID domain 
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phosphorylated  at the residue of Serine 133 (Ser-133), can bind the 
transcriptional coactivator, CREB binding protein (CBP) via its KIX 
domain [196, 197, 198, 199]. As result of the interaction stimulus-
dependent between these two domains, the transcriptional machinery 
starts the synthesis of the inducible genes. Q2/CAD domain interacts with 
components of the basal transcriptional machinery allowing the stimulus-
independent CRE-driven gene expression [200, 201, 202, 203].  
 
I.D.2. DREAM 
DREAM was primarily identified as the transcriptional repressor of the 
human gene for the opioid peptide dynorphin. Dynorphins are members of 
the opioid peptide family which are involved in memory formation and 
chronic pain adaptation. Dynorphin peptide controls the release of 
neurotransmitters as well as it can block LTP in the hippocampus by 
inhibiting excitatory neurotransmission from synaptic terminals [204, 205]. 
The DNA sequence required for the transactivation of prodynorphin 
transcription via cAMP and Ca2+ has been identified in the first exon of the 
gene (at position +40), and termed dynorphin downstream regulatory 
element (DRE) [190]. The transcription factor binding to the DRE was 
subsequently identified and includes four Ca2+ binding domains of the EF 
hand type. Nowadays, it represents the unique transcription factor known 
to be directly regulated by Ca2+. When loaded with Ca2+, DREAM 
undergoes conformational changes causing its detachment from DRE 
sites, thus relieving the transcriptional repression [206,207]. The ability to 
bind DNA of some members of the basic helix-loop-helix (bHLH) 
transcription factor family is also regulated by Ca2+, through the interaction 
with Ca2+-loaded calmodulin [208,209]. 
The DREAM sequence presumably includes four EF-hands, displaying 
high homology to Ca2+-binding proteins of the recoverin subfamily. 
Mutation of two residues within any of the functional EF-hands, the so-
called EFmutDREAMs, did not affect the binding to the DRE but 
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completely prevented the unbinding in the presence of increasing 
concentrations of Ca2+. It seems like the derepression of DRE-dependent 
gene expression after PKA activation [190] is related to specific protein–
protein interactions between DREAM and nuclear effectors of the 
transcriptional effects of cAMP. Analysis of the 5’ regulatory regions of 
many Ca2+-regulated genes has shown the presence of one or several 
functional DRE sites downstream from their TATA boxes [190, 191]. This 
suggests that DREAM mediated transcriptional derepression is a generally 
required step prior to transcriptional activation of many genes.  
A new search showed identity between DREAM and calsenilin, a protein 
able to interact with presenilin-2 found in a yeast two-hybrid screen using 
the carboxy terminal part of presenilin-2 as a bait [210]. Double 
immunostaining after overexpression of N-tagged calsenilin in Cos cells 
showed the colocalization with presenilin-2 in the cytoplasm and the 
endoplasmic reticulum and suggested that the colocalization at the ER, in 
particular, was increased after calcium stimulation [210]. More recently, 
also using a yeast two-hybrid screen to identify components of the protein 
complex responsible for the A-type potassium currents, a protein identical 
to DREAM called KchIP-3 (potassium channel interacting protein 3) was 
found to selectively interact with the amino terminal region of Kv4 
potassium channels [211].  
Interestingly, the interaction with the potassium channel does not depend 
on the presence of calcium. However, the change in KchIP-3/DREAM 
conformation that follows binding to Ca2+ profoundly affects channel 
properties [211]. Interestingly, in this study two other proteins related to 
DREAM, KchIP-1 and -2, were identified. In terms of the interaction with 
potassium channels, KchIP-1 and -2 are similar to KchIP-3. 
However, it is not known whether they are also able to interact with 
presenilin-2 and especially, whether they are able to specifically bind to 
DNA. Thus, the possible existence of a DREAM family of nuclear 
repressors remains to be investigated. Taken together these results 
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indicate that DREAM/KchIP-3/calsenilin might have pleiotropic functions 
through the interaction with specific DNA sequences and/or with proteins 
in different cell compartments [212-213].  
DREAM, calsenilin, and KChIP3 are the products of a unique gene [214, 
215], although the proteins are localized in different cellular compartments: 
nucleus, endoplasmic reticulum, or lysosomes and plasma membrane, 
respectively. Regulation of mRNA translation at alternative start codons 
may generate proteins with variable N-terminal peptides, which could be 
important for their localization and function. Furthermore, isoforms lacking 
the EF-hand domains are generated by alternative splicing in mouse 
[215,192]. 
 
I.D.3. SP transcription family factors 
The Sp/XKLF family (Specificity protein/Kruppel-like factor) is a family of 
transcription factors that share a common structure of cysteine histidine 
zinc fingers. The so-called Cys2His2zinc are conserved sequences placed 
in specific pattern and allow to the factors to bind DNA sequences [216].  
The Kruppel-like factor name comes from the studies performed on the 
segmentation gene discovered in Drosophila. In fact, this gene has been 
discovered to express the same zinc finger motif as well as in the human 
orthologue. In humans, it is well known as Sp1 transcription factor [217]. 
Sp1 factors contact the DNA in threes specific regions of their sequence at 
level of residues KHA, RER and RHK, respectively for the first, second, 
and third zinc finger. 
Sp/XKLF factors bind DNA sequences having the box sequence GC-
(GGGGCGGGG) and GT-(GGTGTGGGG), even changes in aminoacidic 
zinc finger are responsible for their binding affinity. GC and GT boxes play 
a crucial role in the transcriptional events related to the expression of 
housekeeping genes as well as tissue specific and viral genes [216]. 
Interestingly, these motifs have been found to have a role in maintaining 
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the demethylated state in CpG islands, as well as for the adenine 
phosphoribosyltransferase (APRT) genes.  
Sp family includes two major subcategories: Sp1 and KLFs. Sp1 factors 
share a similar structure at the N-terminal side but not at level of their zinc 
finger. KLFs, instead, represent a more heterogeneous group of factors 
[216]. Nowadays, Sp/XKLF family includes many homologies in the 
transcription factors members. In fact, among this family has been 
detected 8 Sp and 15 KLFs factors. Sp factors from 1 to 8 (Sp1-8) 
sequence takes place near the HOX gene cluster. 
Sp1 and Sp7 (Osterix) are placed on the Chromosome 13 at 12q13.13 
(HOX C); whereas Sp2 and Sp6 (KLF14) on 17q21.31/32 (HOXB); Sp3 
and Sp5 on 2q31.1 (HOX D); Sp4 and Sp8 on 7p21.2 (HOX A). The 
regulation mechanism for the transcription of these genes through GC and 
GT boxes is extremely complicated. Moreover, EKLF (Erythroid Kruppel-
like Factor), Sp4 and Sp7 has been discovered to be expressed 
specifically in same tissues as confirmed in in vivo experiments with mice 
[218, 219]. Sp1 and Sp3 are homely expressed albeit expressing specific 
functions are shown in gene ablation studies [220]. 
 
I.D.4. Structural Characteristics of the Sp Factors 
Sp1 was primarily identified as trans-activator factor of the SV40 early 
promoter [221]. In the past, many works considered Sp1 as an essential 
factor for the regulation of transcription of the genes having GC or GT 
boxes . Anyway, this thought was abandoned when different transcription 
factors, called Sp2, 3 and 4, were cloned. Later, they discovered also Sp5, 
Sp6 or KLF14, Sp7 or Osterix and Sp8 [222]. Sp5-8 share various brief 
domains with Sp1-4. Among the Sp factors from 1 to 4, (Sp1, Sp2, Sp3 
and Sp4) the presence of similar modular structure make possible to 
include these four factors in a subgroup. Instead, Sp1, Sp3 and Sp4 
contain two principal glutamine-rich transactivation domains named A and 
B  involved in the transcription activation. A series of serine/threonine-rich 
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sequences are placed adjacent to the A and B domain, being a possible 
target of post-translational modification. Sp2 factor has a unique 
glutamine-rich domain albeit it presents a highly charged domain C and a 
serine/threonine-rich region in common with the other factors. Sp2 
displays a different consensus-binding site as consequence of a 
substitution of a residue of histidine with a leucine residue in zinc finger 1 
[223]. The Sp factors generally have in their sequence a box following N-
terminal to the zinc finger domain named Buttonhead box [224]. The 
Buttonhead box (Btd element) includes a sequence of 11 conserved 
amino acids having a possible role in the transactivation potential of the 
factors as confirmed by the deletion of an overlapping region that induce a 
reduction in Sp1 activity in vitro [225].  Moreover, domain C, and primarily 
its Btd element  [226], are involved in activation SREBP-mediated (sterol-
regulatory element-binding proteins) of Sp1 or Sp3. Harrison and 
collegues in 2000 identified another conserved sequence, named Sp box 
(SPLALLAATCSR/KI), at level of the N-terminus of the proteins. Closely to 
the N-terminus, this element contains an endoproteolytic cleavage site that  
functions as target proteasome-dependent degradation in vitro [227]. 
Even not required for cleavage, the highly conserved sequence of the Sp1 
box indicates that could have a role in regulation of Sp factors proteolysis. 
Another possible role for the Sp box could refer to the control of 
transactivation potential through interaction with a presumed repressor 
[228]. Although the functions of the Btd and Sp boxes are not completely 
clear, their absence in the XKLF subgroup suggest a relationship between 
the Sp transcription factors. Moreover, the N-terminal regions of Sp5-8 are 
completely different, except for the Btd and the Sp boxes, from those of 
Sp1-4 and more closely related to each other.  
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I.D.5. Early growth response-1 (EGR-1) 
Egr-1 is a member of immediate early genes and it has three C2H2 zinc 
fingers DNA-binding domains that can recognize GC- rich sequences of 
target genes. This transcription factor can be induced rapidly by various 
stimulants such as growth factors, neurotransmitters, stress and injury. 
EGR-1 is widely expressed in the brain and regulates the transcription of 
different target genes, among these BDNF is one of the most important. In 
particular, several studies suggest a detrimental role for EGR-1 because 
of its upregulation after ischemic stroke [229]. Interestingly, it has been 
demonstrated that after ischemic insult, EGR-1 was upregulated and by 
binding the promoter of BDNF gene decreased its expression. This 
mechanism leads to a worsening of ischemic injury by attenuating 
neuroprotective effects of BDNF [230].     
 
I.D.6. Activator protein 2 (AP-2) 
Transcription factor AP-2α (TFAP2α) belongs to AP-2 family transcription 
factors which consists of five members either in humans and in mice. All 
AP-2 transcription factors are encoded by seven exons except for AP-2δ, 
and they share, at the carboxyl terminus, a highly conserved domain 
consisting in a helix-span-helix that is able to determine the dimerization 
and the binding to DNA in concert with a central basic region. In fact, 
these transcription factors are capable of forming heterodimers or 
homodimers. The N-terminal region comprises the transactivation domain, 
rich in proline and glutamine. AP-2 transcription factors have a nuclear 
localization because of their particular role in regulating gene transcription.  
AP-2 proteins are able to establish a cross-talk with several transduction 
pathways; for example they modulate the pathway of the developmental 
signaling molecule Wnt. AP-2 factors are susceptible of several 
posttranslational modifications such as PKA phosphorylation and 
sumoylation, and they can associate with other various transcription 
factors like p300, Sp-1, p53. In mice AP-2α, AP-2β and AP-2 γ, are widely 
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expressed in neural crest cells, in nervous system and throughout the 
epithelia [231].  
 
I.E. PHARMACOLOGICAL REGULATION OF NCX3  
EXCHANGER ACTIVITY 
The search for drugs capable of modulating the activity of NCX is evidently 
more important in function of its possible therapeutic use for those 
pathological states in which NCX has been proved to be altered. 
  
I.E.1. Inhibitors 
 
Inorganic cations 
The Sodium Calcium Exchanger NCX is well known to bind many different 
cations [232]. Among these, many exert an inhibitory effect due to the 
direct binding to NCX molecules or via competition with Ca2+ thus working 
as substrate for the antiporter. In fact, Ni2+ inhibits the exchanger when it  
works in reverse mode [232], probably through a competition mechanism 
that hinders the external transport of Ca2+[232]. The affinity of Ni2+ for the 
three isoforms of NCX is variable. Notably, NCX3 displays a minor 
sensitivity to Ni2+ or Co2+ in the order of 10-fold compared to NCX1 or 
NCX2 [232]. Recently, in NCX1 it was discovered a sequence of three 
aminoacids involved in the Ni2+ specific sensitivity, respectively Asp-130 at 
level of the alpha1-repeat, and Asp-825 and Glu-837 in the alpha2-repeats 
[233]. 
Peptides 
A wide number of peptides are mentioned to inhibit the activity of the 
exchanger. 
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Endogenous Exchange Inhibitory Peptides 
Within the f loop dwells a sequence of 20 amino acids, called XIP, which  
plays its auto-inhibitory effect via a mechanism dependent by Na+ 
[234,235]. The same sequence in a synthetic peptides exerts the same 
inhibitory function on the exchanger. XIP is reported to block both forward 
that reverse operation mode of all the three isoforms of NCX, since they 
share a similar XIP structure sequence. The three specific regions, named 
XIP1, XIP2, and XIP3 have a very conserved sequences despite some 
little amino acidic-residue variations [236,237]. When the ligand binds the 
XIP sequence, a conformational change in C-terminus of the f loop occurs,  
leading to inhibition of ionic transport [238]. This effect is selectively 
allowed by the presence of a specific sequence between the aminoacids 5 
and 16 of XIP [236,238]. Remarkably, basic and aromatic residues found 
in this sequence play a crucial role of the XIP-mediated inhibition. It has 
been synthetized a XIP bearing a molecule of glucose attached to the 
Tyrosine 6 residue, since the glycosylated peptide more efficiently 
penetrates the cells. In fact, the link with the glucose allows to the peptide 
associated to enter the cell via the glucose transporters 1 and 3 [239]. It is 
interesting to note that male rats infused intracerebroventricularly with the 
glycosylated form of XIP, express an enormous increase of the infarct 
volume after Permanent Middle Cerebral Artery Occlusion (pMCAO) [240]. 
These findings suggest a possible important role for NCX modulation in 
case of the dramatic effect of neuronal death under ischemia. 
Heterocycles 
 
Amiloride Derivatives 
Amiloride has been discovered to block NCX activity when used at 
millimolar concentrations [241].  Its effects are also evident in the inhibition 
of both epithelial Na+ channel when used in micromolar concentrations 
that in Na+/H+ exchanger when it is used in the order of millimolar. 
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Remarkably, this further effect is cause of lack of specificity for the 
exchanger Na+/Ca2+ NCX. To this aim, in the last year new amiloride 
analogs have been synthetized. Among the different classes of analogs for 
amiloride developed, the first class of molecules does not display an 
inhibitory effect on the epithelial Na+ channel and plasma membrane NCX, 
albeit its effect is more evident on Na+/H+ exchanger, when it is used in 
concentrations that may oscillate between 1 to 10 μM [242, 243,244]. 
Conversely, the second class of amiloride analogs are selective for 
epithelial Na+ channel and NCX but not for the Na+/H+ exchanger. Notably, 
three specific compouds belonging to the second group, the 
dimethylbenzamyloride (DMB),  the 3’-4’-dichlorobenzamyl, and the alpha-
phenylbenzamil, have been discovered to selectively block the NCX in 
excitable cells like neurons  [242, 243]. Another analogue, the [N-(4-
chlorobenzyl)]2,4-dimethylbenzamyl (CB-DMB), is described as the better 
inhibitor for NCX activity, whereas it does not present an inhibitory effect 
on Na+/H+ antiporter neither for the epithelial Na+ channels (Ki > 400 μM) 
[241]. Amiloride analogs efficiency is evident in blocking NCX activity both 
in forward [243] than in reverse operating mode [245], in fact they compete 
with Na+ ion in a reversible manner binding.  Notably, it has been recently 
proposed this category of molecules as Na+ analogs, indeed they interact 
with the third Na+-binding site, acting as inactivators of the exchanger 
[246]. 
 
Diarylaminopropylamine Derivatives: Bepridil 
Among the dyarilaminooripylamine derivates, the inhibitory effect of 
Bepridil is exerterd on various ionic mechanisms, including the Ca2+ 
current mediated through L- [247] and T-Type channels [248], the delayed 
rectifier K+ currents, the transient outward current [249], the K+ current, 
activated by intracellular Na+ [250]. Moreover, Bepridil acts also blocking 
the NCX activity, albeit the effect is dependent by the operation mode of 
the exchanger [251]. In fact, the Bepridil is more specific in blocking the 
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NCX activity working in the forward mode than in reverse. Recently, it has 
been discovered that Bepridil acts on the intracellular portion of the NCX, 
since its inhibitory effect is lost when cells were treated intracellularly with 
trypsine [251]. Experimental use of Bepridil, respectively in a model of 
Chemical Hypoxia in vitro and Ischemia in vivo (pMCAO), induced a 
further glial and neuronal damage [252,240]. 
I.E.2. Activators 
 
Inorganic Cations 
Lithium may stimulate, even if with minimum affinity, the Ca2+ intake 
through a mechanism dependent by the intracellular concentrations of Na+ 
for all the NCX isoforms. Its effect is quite low for NCX1 rather than in 
NCX2 or NCX3 [232]. NCX1 chimeras generated by substitution with the 
α-2 repeat of NCX3, present a greater sensitivity to Lithium similar to that 
one described for the isoform 3 of the exchanger NCX. By contrast, the 
chimeras containing the α-2 repeat of NCX1 expressed in NCX3 
presented a loss on lithium sensitivity in NCX3 with values similar to the 
native NCX1. These findings suggest that the the α-2 repeat is required for 
both stimulation of NCX isoforms, either in NCX1 that in NCX3 [232,253]. 
 
Redox agents 
NCX activity is highly sensible to the redox state, since the presence of 
reducing compounds and oxidating agents induces the activation of the 
Sodium Calcium Exchanger. Among molecules that influence the redox 
state and consequently the functional activity of NCX we remember 
reducing substrates in the form of glutathione (GSH), 1,4-Dithiothreitol 
(DTT), Fe2+, O2- superoxide and oxidating agents like Fe3+, H2O2, 
glutathione disulfide (GSSG) and O2  [254]. It was proposed that these 
agents could activate the exchanger activity by promoting thiol-disulfide 
interchange in the protein carrier [254]. Recent studies suggest that the 
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activation of NCX activity may be due to the reduction of disulfide bond 
with a consequently formation of new link [254]. Cystein residues 
associated with the formation of disulfide bonds are presumably the Cys-
14, Cys-20, and Cys-780 [255]. The analysis of mutated exchangers has 
indicated that cysteines are not responsible for the stimulation of the 
exchange activity induced by a mixture of redox agents [255]. It has been 
suggested that the stimulation of wild-type exchanger by Fe-DTT is mainly 
due to the removal of the Na+-dependent inactivation process [255]. Since 
redox changes in NCX activity have been implicated in several aspects of 
cell physiology and pathophysiology, it is possible to speculate that agents 
capable of stimulating NCX might constitute a possible therapeutic 
strategy in those pathological conditions in which oxidative stress is 
involved [256]. 
 
Organic compounds 
Agonists of G-Protein-Coupled Receptors 
It has been reported that the agonists of G-protein-coupled receptors, 
such as α- and β-receptors, histamine, 5HT2c, and endothelin-1 and 
angiotensin-II receptors, are capable of stimulating NCX activity by a 
pathway which involves either PKA and/or PKC [257, 258, 259, 260, 261, 
262]. 
 
Peptides 
Among the peptides capable of stimulating NCX activity, only insulin and 
concanavalin A have been proven to exert such effect. In fact, both 
peptides stimulate Na+-dependent Ca2+ uptake [263, 264]. 
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I.F. ROLE OF NCX3 EXCHANGER IN 
PATHOPHYSIOLOGICAL CONDITIONS 
 
NCX3 by controlling intracellular homeostasis of calcium and sodium, may 
play a crucial role in ischemic event. NCX3 assumes two different 
behaviours in the ischemic core region and in the penumbral region. In the 
first case, ischemic insult brings to an accumulation of intracellular Na+ 
ions because of Na+/K+ pump failure, forcing NCX3 to operate in reverse 
mode. In the penumbral region, NCX3, sustained by ATPase activity,  
operates in forward mode extruding calcium ions and decreasing cell 
injury. It has been demonstrated that permanent middle cerebral artery 
occlusion (pMCAO) is able to cause changes in NCX protein expression in 
ischemic core and in penumbral region. In particular, 6 to 24 hours after 
pMCAO, NCX3 decreased in the ischemic core; this event was probably 
due to the cleavage of NCX3 protein, aroused by the activation of 
caspases and calpain during ischemia suggesting that the decrease of 
NCX3 can be involved in the process leading to cell death. By the injection 
of specific antisense oligodeoxynucleotides (AS-ODNs), NCX1, NCX2 and 
NCX3 gene products were knocking down. The rats knocking down for 
NCX3 displayed enlargement of the infarct volume with a worsening of 
neurological deficits [265]. It has been demonstrated that BHK (Baby 
hamster kidney) cells stably transfected with the isoform 3 of sodium 
calcium exchanger, unlike those transfected with NCX1, NCX2 or wild-
type cells,  displayed a major resistance to chemical hypoxia plus 
reoxygenation by virtue of their Ca2+ buffering properties in conditions of 
ATP depletion. NCX3 is the unique isoform able to operate in absence of 
ATP, whereas NCX1 and NCX2 are strictly dependent by this nucleotide 
for their action [266]. These data suggest a relevant role for NCX3 in 
counteracting ischemic damage. 
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A further demonstration of the neuroprotective role of NCX3 in brain 
ischemia is provided by knockout mice (ncx3-/-) for this isoform of the 
exchanger. In primary cortical neurons and in organotypic hippocampal 
cultures obtained from NCX 3 -/-  mice and subjected to OGD plus 
reoxygenation, neuronal death was increased after ischemic insult 
compared to wild-type mice.  Furthermore, ncx3 gene suppression leads 
to a worsening of brain damage  after tMCAO [267]. 
It has been demonstrated that NCX3 is potentially neuroprotective in a 
model of Alzheimer’s disease. In neurons, the exposure to amyloid-β 1-42 
(Aβ 1-42) determines an early increase in intracellular calcium concentration 
that triggers the activation of calpain. Calpain generates NCX3 
hyperfunctional proteolytic fragment with a consequential increase of 
NCX3 currents in reverse mode of operation. In particular, the enhanced 
NCX3 activity contributes to increase calcium content in endoplasmic 
reticulum (ER), thus delaying ER stress and cell death. In the late phase, 
when the NCX3  proteolytic cleavage cesead, a reduction in ER calcium 
content happens, thus triggering ER stress and consequential neuronal 
death. These results suggest that neurons activate via NCX3, an early 
survival strategy against the deleterious stimulus represented by Aβ- 1-42 in 
the early phase of their exposure to this peptide [268]. NCX3 is highly 
expressed in CA1 and CA3 regions, the hippocampal subfields involved in 
long term potentiation (LTP), suggesting a role for this exchanger isoform 
in learning and memory [269, 256]. Because of NCX3 plays a crucial role 
in removing calcium at the synaptic site of hippocampal neurons [270], it 
has been investigated its role in LTP modulation. Ncx3 -/- neurons showed 
an alteration of LTP caused by the reduction of NCX currents in the 
forward mode of operation. Indeed, the ablation of NCX3 gene, delaying 
intracellular calcium removal after neuronal activation and increasing  the 
intracellular concentration of this ion in resting conditions, decreases the 
magnitude of LTP at hippocampal Schaffer collateral-CA-1 synapse level. 
NCX3 knockout mice displayed a significant reduction in spatial-learning 
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and memory performances compared to wild-type mice, demonstrating a 
key role of this exchanger isoform in learning phenomena [271]. 
 
I.G. TRANSCRIPTIONAL REGULATION OF NCX3 GENE IN 
NEURONS AND NEURONAL CELLS 
 
I.G.1. Regulation of NCX3 promoter activity by DREAM in cerebellar 
neurons 
The human NCX3 proximal promoter contains specific enhancers such as 
cAMP response element (CRE) [169]. Gomez- Villafuertes and colleagues 
have demonstrated a specific role for DREAM in regulating Ca2+ 
homeostasis and viability in cerebellar neurons. NCX3 is the most 
abundant Na+/Ca2+ exchanger in cerebellar granules, and excitotoxins 
through the action of calpains trigger the rapid degradation of this 
exchanger isoform. NCX3 plays a crucial role in the maintenance of Ca2+ 
homeostasis in these neurons, underlying the importance of sheding light 
on the mechanism regulating NCX3 expression in neurons. DREAM 
through a mechanism Ca2+ dependent can modulate the expression of 
several genes and it has been found to bind to specific DRE sites to 
repress transcription [272]. Binding of Ca2+ to DREAM via EF-hand motifs 
reduces its affinity for DNA, leading to its detachment from the DRE sites 
and to derepression of target genes. DREAM – dependent transcriptional 
derepression is also observed after protein kinase A (PKA) activation 
through a mechanism that involves the interaction of DREAM with 
phosphorylated α-CRE modulator (α-CREM). DREAM interacts with CREB 
in Ca2+- dependent manner and represses CRE- dependent transcription, 
preventing the recruitment of CBP [191].  In the kinase‐inducible domain 
(KID) of CREB and in leucine zipper of αCREM there are two 
leucine‐charged residue‐rich domains (LCD) that are able to interact with 
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other two LCDs in DREAM, this physical interaction led to the loss of 
DREAM binding to DRE sites and derepression. 
Since the LCD motif located within the KID in CREM is also present in 
CREB, and maps in a region critical for the recruitment of CBP, in the 
absence of Ca2+ DREAM binds to the LCD in the KID of CREB [191]. As a 
result, DREAM impairs recruitment of CBP by phospho CREB and blocks 
CBP‐mediated transactivation at CRE sites in a Ca2+‐dependent manner.  
Gomez-Villafuertes and colleagues have demonstrated that DREAM 
mediates ncx3 gene repression in the cerebellum of transgenic mice 
overexpressing the Ca2+- insensitive EF-hand mutant EF-m-DREAM. So, 
transgenic cerebellar granules have increased levels of cytosolic Ca2+ and 
are less viable when cultured under mild membrane-depolarizing 
conditions. Importantly, their viability is normalized when their 
Ca2+ extruding ability is restored by lentiviral-mediated overexpression of 
NCX3. Thus, the Ca2+-modulated transcriptional repressor DREAM 
controls the expression of the NCX3 protein, which is fundamental for the 
maintenance of the Ca2+ homeostasis and viability of the neurons [272]. A 
cAMP-dependent regulation of the NCX3 promoter has been associated 
with the presence of a CRE site [169].The EFmDREAM mutant has an 
intact leucine-charged residue rich domain, which is responsible of the 
interaction with CREB but does not respond to Ca2+ stimulation, so it 
should heterodimerize with CREB and function as a dominant mutant to 
also block the CRE-dependent transcription of the NCX3 gene [191]. 
Thus, the synergistic stimulation of the NCX3 gene by Ca2+ and cAMP 
signaling would be blocked by the dominant EFmDREAM. The regulation 
by DREAM is specific for the NCX3 gene, because the DREAM mutant 
does not affect the transcription of NCX1 and NCX2 [191, 272]. 
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I.G.2. Regulation of NCX3 promoter activity by CREB in SH-SY5Y cell 
line 
In proliferating and differentiated SH-SY5Y cells, it has been investigated  
the regulation of the transcription of SLC8A3 promoter following the 
elevation of cAMP and the intracellular calcium increase obtained by 
partial depolarization of the plasma membrane with KCl.  In proliferating 
and differentiated cells, the SLC8A3- reporter activity was increased about 
two fold following treatment with the membrane permeable cAMP 
derivative N6, 2′-O-Dibutyryladenosine-3′:5′- cyclic monophosphate 
(Bt2cAMP). The induction triggered by cAMP was abolished owing to the 
reporter construct lacking the CRE site in both proliferating and 
differentiated cells, demonstrating a pivotal role of CRE site in the increase 
of the SLC8A3- reporter activity cAMP-dependent. In proliferating cells, a 
partial depolarization of the plasma membrane is achieved through KCl 
and allows calcium entry. This depolarization that affects the plasma 
membrane downregulated the transcription of the SLC8A3 promoter via 
calcium of about 40% compared to untreated control cells. The activity  of 
the reporter construct lacking the CRE site decreased by the Ca2+, was 
similar to that displayed by the wild-type promoter, indicating that the CRE 
was not involved in this downregulation. The downregulation that occurs in 
basal transcription activity could be produced by CaMKII (Ca2+ 
/calmodulin-dependent protein kinase II) phosphorylation of CREB at Ser-
142 [169,192]. The negative effect of Ca2+ on basal SLC8A3 transcription 
could depend on the downregulation of AP2 consequent to the activation 
of PLC (phospholipase C) and PKC (protein kinase C) after depolarization 
with KCl, shown to occur in SH-SY5Y cells [273,274]. When cAMP and 
Ca2+  levels were raised simultaneously, it is possible to appreciate the 
inhibitory effect of the Ca2+ elevation. In this case, the CaMKII inhibitor KN-
93 reversed the downregulation of the cAMP-stimulated activity by Ca2+ 
[275]. 
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Furthermore, to support the involvement of CaMKII activity in this 
downregulation, it has been evaluated the immunoreactivity of anti-
phospho Ser-133 following the cAMP and Ca2+ elevation. CREB was 
strongly phosphorylated following the cAMP increase, contrary to what 
happens after the depolarizing treatment. However, when cAMP and Ca2+ 
were elevated simultaneously, phospho-CREB was reduced, raising the 
possibility that phosphorylation of the Ser-142 by the CaMKII could 
decrease the affinity of the antibody to anti-phospho Ser- 133. However, 
data were not conclusive because the possibility that KN-93 inhibitor could 
instead block Ca2+ entry through VGCC was not ruled out [276,277]. 
Furthermore, the cAMP-stimulated activity of the promoter lacking the 
CRE site was strongly downregulated by Ca2+ in proliferating cells.  
By contrast, calcium induced SLC8A3 promoter in fully differentiated 
neurons exposed to BDNF for 4 days via ATF/CREB family, in fact the 
absence of CRE/CaRE sequence disrupted this induction. BDNF is one of 
the main regulators of CREB-induced gene transcription and it is an 
activator of SLC8A3 gene expression in stably transfected cells. The 
deletion of the CRE element in the SLC8A3 promoter causes the loss of 
stimulation by BDNF [275]. The phosphorylation of CREB obtained via 
CaMKII and CaMKIV leads to an increase of promoter activity, in fact 
CaMKs activation could be triggered during the differentiation promoted by 
BDNF in neuroblastoma cell line. It was also observed a different 
phosphorylation pattern of ATF/CREB polypeptides in response to the 
cAMP elevation in differentiating neurons. BDNF, during the first day of 
exposure, induces cAMP elevation and apparently causes the 
phosphorylation of transcription factor ATF1 instead of CREB [275]. It is 
possible that specific isoforms of CaMKs could be upregulated in 
differentiated neurons. CaMKII can phosphorylate Ser-63 of ATF-1, 
corresponding to Ser-133 of CREB, but is unable to phosphorylate Ser-72 
of ATF-1, corresponding to the inhibitory Ser-142 of CREB. Therefore 
transcription factor ATF-1 can be only positively regulated by CaMKII, 
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suggesting that transcriptional activation of cAMP-responsive genes by 
CaMKII may be mediated by ATF-1 [278], in fact the Ca2+ elevation does 
not change the extent of anti-phospho Ser-133 immunoreactivity; however 
it is also possible that the activation of CaMKII and CaMKIV by BDNF 
induces the phosphorylation of CREB at Ser-142 and Ser-143. The triple 
phosphorylation of CREB at Ser-133, Ser- 142, and Ser-143 [279] is 
induced by calcium influx, thus these phosphorylations that occur in these 
peculiar serines disrupt the interaction of the KIX domain of CREB with 
CBP, forming a transcription complex different from that induced by cAMP. 
For this reason, calcium pathway may trigger a specific program of gene 
expression that is different from that induced by cAMP. The triple 
phosphorylation of CREB, responsible of the increased transcription status 
of the SLC8A3 gene via calcium, occurred in embryonic cortical neurons 
(E18) cultured for 6–8 d but was absent in the earlier stages. In 
conclusion, the upregulation of SLC8A3 transcription by Ca2+ influx is 
greater in fully differentiated SH-SY5Y exposed to BDNF for 4 d than in 
cells exposed to BDNF for 1 d [169-192].  
 
I.H. MODULATION OF NCX3 EXPRESSION IN IN VIVO AND 
IN VITRO MODELS OF STROKE 
I.H.1. NCX3 gene is downregulated in brain ischemia and upregulated 
in postconditioned ischemic brain  
Recent studies explored a new neuroprotective mechanism as potential 
therapeutic treatment in case of an ischemic stroke episode. A short but 
sublethal ischemic event, the so-called ischemic post-conditioning, has 
been found to prevent the harmful effects of primary prolonged ischemia 
[280]. It has been investigated the role played by the different isoforms of 
the Na+-Ca2+ exchanger NCX (NCX1, NCX2 and NCX3) during the post-
conditioning. To this aim, it has been evaluated the expression of the NCX 
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isoforms in the ipsilateraltemporoparietal cortex of rats exposed to 
ischemic post-conditioning event. The expression levels of NCX isoforms 
in postconditioned rats were compared with those of rats which received 
the tMCAO alone [281]. 
The reduction in NCX3 expression occurring in cerebral ischemia alone 
was completely prevented by ischemic post-conditioning. Interestingly, the 
NCX3 protein expression showed an increase 24 hours after post-
conditioning. 
In order to evaluate whether this NCX3 protein increase was due to a 
stimulation of transcriptional events, the levels of mRNA coding for NCX3  
were analyzed. Notably, mRNA levels from the ipsilateraltemporoparietal 
cortex of rats subjected to ischemic post-conditioning at different 
reperfusion time intervals were analyzed through Real-Time Polymerase 
chain reaction (RT-PCR) and were compared with those of the same brain 
region of rats subjected to ischemia alone [281]. 
After ischemia, the NCX3 mRNA expression was found reduced 
approximately of 50% at 24 hours after reperfusion, whereas in post-
conditioned animals from 5 to 24 hours after reperfusion NCX3 mRNA 
expression progressively increased compared with sham-operated 
animals [281].  
 
I.H.2. NCX3 sumoylation participates in SUMO1 protective role during 
ischemic preconditioning 
NCX3 is susceptible also for new post-transcriptional modifications such 
as sumoylation. The Small Ubiquitin-like Modifier (SUMO) conjugation has 
been described as enzymatic modification of target proteins via covalent 
binding of SUMO substrate. As the sumoylation protects the target 
proteins from degradation, it allows the modulation of intracellular protein 
localization, activity and stability [282]. Among the SUMO proteins, four 
isoforms have been identified (SUMO 1 to 4). SUMO 1, SUMO 2 and 
SUMO 3 are expressed in the brain, whereas the fourth isoform (SUMO 4) 
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is mainly localized in the kidney [283]. The sumoylation modification is 
promoted by different stress conditions. In case of focal cerebral ischemia, 
a different cerebral sumoylation pattern was described [284], and it may 
play a neuroprotective role. In fact, SUMO-1 knock down mice showed 
decreased cell survival to the Oxygen-Glucose Deprivation (OGD) model, 
whereas overexpression of SUMO 1 has been found to protect neurons 
from OGD-induced injury. Interestingly, among the several neuroprotective 
molecules supposed to play a crucial role in the ischemic preconditioning, 
some of these have been described also as possible substrates for 
sumoylation [285]. Emerging evidences support the role for sumoylation in 
ionic homeostasis modulation. In fact, recent studies confirmed the 
presence of sumoylation enzymes and substrates at the plasma 
membrane, thus sumoylation might regulate stability and expression of the 
transmembrane proteins interested in the brain ischemia event, 
specifically NCX3. SUMO1 is involved in the neuroprotective mechanisms 
elicited by in vivo ischemic preconditioning. NCX3, a downstream key 
player of neuroprotection in stroke [265,154,286] has also been proposed 
as a new possible target of SUMO1. In rats subjected to tMCAO, the 
silencing of SUMO1 significantly worsens the ischemic injurious outcome 
and partially reverted the preconditioning-mediated neuroprotective 
effects. 
Double immunofluorescence analysis for NCX3 and SUMO1 revealed a 
neuronal signal increase of the two proteins in both preconditioning and  
preconditioning followed by tMCAO, suggesting a possible spatial and 
temporal interaction between NCX3 and SUMO1. Bioinformatic analysis of 
NCX3 sequence displayed the presence of nine putative sumoylation sites 
that might be recognized by SUMO1. In fact, deletion mutagenesis 
experiments demonstrated that the removal of either the whole f-loop 
(252-750 aa), or its subregion (528-676 aa), prevented the co-
immunoprecipitation of NCX3 with SUMO1. This suggests that NCX3 
sumoylation site was located in the 528-676 aa region of the f-loop, a 
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region involved in the regulation of NCX stability and activity [34,35].  
Interestingly, the SUMO1 silencing produced a downregulation of NCX3 
protein levels during preconditioning plus tMCAO ischemic model, 
suggesting a role for SUMO1 in mediating a protection related to NCX3. 
Consequently, all these findings present a possible neuroprotective role in 
which the NCX3 sumoylation mediated by SUMO1 may prevent 
degradation of NCX3 occurring during ischemic conditions. Furthermore,  
NCX3 might be one of the SUMO1-mediated neuroprotective mechanisms 
involved in ischemic preconditioning [287]. 
I.H.3. OGD/Reoxygenation - induced NCX3 downregulation at post-
transcriptional level 
Cortical neurons deprived for three hours of oxygen and glucose (OGD in 
vitro model) expressed lower amount of NCX3 protein compared to control 
neurons. Interestingly, this effect was not found for NCX1 which protein 
expression levels remained unaffected [288]. The downregulation of NCX3 
did not affect the relative transcript decrease in turn, suggesting a possible 
effect exerted by anoxic and scarce energetic conditions on protein 
expression through post-transcriptional modifications [288]. In fact, the 
downregulation of NCX3 in cortical neurons exposed to OGD conditions 
was prevented by using the inhibitor for the proteasomal system, the MG-
132, safeguarding the basal protein expression, whereas three hours of 
OGD has been found to downregulate NCX3 protein expession via 
proteasomal system activation [288].
  
 
 
Aim of Study 
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II. AIM OF STUDY 
The human gene for member 3 of solute carrier family 8 (SLC8A3), 
encoding the Na+/Ca2+ exchanger isoform 3 (NCX3), was identified on 
chromosome 14q24 and consists of nine exons. Three different splicing 
isoforms have been found for NCX3, and specifically in the brain the 
exons 3 and 5 are spliced to form an mRNA that contains only seven 
exons [275]. NCX3 minimal promoter sequence has been described and it 
is located at 250 bp region upstream of exon-1 [275]. The consensus 
sequences for specific transcription factors have been identified in this 
minimal promoter via bioinformatic analysis. Among the transcription 
factors able to bind this promoter sequence, it has been found that the 
transcriptional repressor DREAM and the transcriptional activator CREB 
decrease and increase NCX3 promoter activity, respectively [275,272]. 
NCX3  plays an important role in neuronal survival in in vitro and in vivo 
models of cerebral ischemia [267]. In fact, the ischemic brain damage is 
significantly increased by NCX3 knocking - down [267], whereas during 
ischemic preconditioning (a well-known mechanism of neuroprotection) 
there is an increase of NCX3 [154]. About transcriptional regulation of 
NCX3 it has been found that after ischemia NCX3 mRNA expression was 
reduced approximately of 50% at 24 hours [281] while in ischemic  
postconditionig ncx3 mRNA is increased of 40% [154,281]. Regarding the 
transcription factors and the epigenetic mechanisms regulating NCXs, it 
has been found that NCX1 isoform is reduced in brain ischemia by 
Sp3/REST/HDAC1/HDAC2 complex [156] whereas it is increased in 
ischemic brain preconditioning by Sp1/HIF- 1/p300 complex [155], and 
these changes in NCX1 expression are achieved trought modifications of 
histone acetylation status of ncx1 promoter. The epigenetic mechanisms 
such as histone acetylation of NCX3 promoter and consequent changes in 
NCX3 expression in neurons have never been investigated. The first aim 
of this study was to evaluate the role of HDACs inhibitors (acting on class I 
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and II of HDACs) on the modulation of NCX3 gene and protein in primary 
cortical neurons (DIV 7). We found that pan HDAC inhibitor TSA and 
HDAC class IIa inhibitor MC1568 both increased ncx3 promoter activity. 
Importantly, MC1568 increased NCX3 mRNA at 24h and 48h. 
Furthermore, the other aims of this thesis were to identify the specific 
isoform or isoforms of HDACs belonging to class II involved in the 
regulation of ncx3 expression and the correlation between the expression 
of specific HDACs isoforms and ncx3 gene activity in in vivo models of 
ischemic stroke. 
  
 
Material and Methods 
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III. MATERIALS AND METHODS  
III.1. Materials 
Luciferase reporter kits and luciferase vectors were from Promega (Milan, 
IT). Synthetic oligonucleotides were from Primm (Milan, IT). siRNAs for 
HDAC4 (siHDAC4) (SI01836492), HDAC5 (siHDAC5) (SI01521002), 
HDAC7 (siHDAC7) (SI05620702), HDAC9 (siHDAC9) (SI02024995) were 
from Qiagen (Milan, IT). The HDAC inhibitor MS-275 (EPS002), MC1568 
(M1824) and trichostatin A (TSA) were obtained from Sigma (Milan, IT). 
These three compounds were dissolved in dimethyl sulfoxide (DMSO) and 
diluted before application to a final DMSO concentration lower than 0.2%. 
All common reagents were of the highest quality and were purchased from 
Sigma (Milan, IT).  
 
III.2. Primary Cortical Neurons 
Primary cortical neurons were prepared from 17-day-old Wistar rat 
embryos (Charles River, Calco, IT) and used after 7 days. Cytosine 
arabinoside (2.5 μM) was added the second day to reduce glial 
contamination. The experiments on primary cortical neurons were 
performed according the procedures described in experimental protocols 
approved by Ethical Committee of the “Federico II” University of Naples. 
Briefly, dissection and dissociation were performed in Ca2+/Mg2+-free 
phosphate-buffered saline (PBS) containing glucose (30 mM/l). Tissues 
were incubated with papain for 10 minutes at 37°C and dissociated by 
trituration in Earl’s Balanced Salt Solution (EBSS) containing DNAse (0,16 
U/ml), bovine serum albumin (10 mg/ml), and ovomucoid (10 mg/ml). 
Neurons, were plated in plastic Petri dishes (Falcon™ Becton-Dickinson, 
Buccinasco, IT) pre-coated with poly-D-lysine (20 µg/ml), were grown in 
MEM/F12 containing glucose, 5% of deactivated fetal bovine serum (FBS) 
and 5% of horse serum (HS), glutamine (2 mM/l), penicillin (50 Units/ml), 
and streptomycin (50 μg/ml) (Invitrogen, Milan, IT). Cell density was 2x106 
cells/well for 12-well plate for luciferase assay, 5x106 cells/well for 60 mm 
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for qRT-PCR and 15x106 cells/well for 100 mm for Western Blot analysis 
and ChIP analysis. 
 
III.3. Transfection with Expression Plasmids or Small Interfering RNA 
(siRNA) and Luciferase Reporter Assay, in Cortical Neurons  
Cortical neurons were transfected with 50nM of siCTL, siHDAC4, 
siHDAC5, siHDAC7 or  siHDAC9. For RNA interference, 50nM of specific 
siHDAC4, siHDAC5, siHDAC7 or siHDAC9 were used. To overexpress 
HDAC4, HDAC5, and HDAC9 neurons were transfected with above 
mentioned constructs in the following amounts: 1.3 μg for 12-well plates, 7 
μg for 60 mm plates and 15 μg for 100 mm plates. Each transfection was 
performed at 7 DIV in Optimem with Lipofectamine LTX (15338-100, 
Invitrogen, Milan, IT), as suggested by the producer. After 2 hours it was 
replaced with fresh medium. For luciferase assay experiments, cortical 
neurons at 7 DIV were transfected in 12-well plates. Cells were co-
transfected with 1.2 μg of total DNA vectors; the reporters (800 ng each) 
were the following: (1) the pGL3 construct, (2) the pGL3-ncx3 (short ncx3 
promoter), (3) the pGL3-ncx3-CREmut (GACGT), (4) the pGL3-ncx3-
DREmut (GTCAGTCA). Mutagenesis of the CRE and DRE sites in the 
promoter was performed using the QuickChange site-directed 
mutagenesis kit from Stratagene. Each transfection mix also contained 
140 ng of the pRL-TK control vector expressing renilla luciferase gene. 
After a 2h incubation period, the medium was replaced with a fresh one 
and analyzed after 24h with Dual-Luciferase Reporter Assay System kit 
(E1910) (Promega, Milan, IT), as already reported [289].  
 
III.4. Quantitative Real-Time PCR (qRT-PCR) Analysis 
The first-strand cDNA and quantitative real-time PCR was carried out as 
previously described [289, 290]. Using 1/10 of the cDNAs as a template, 
the quantitative real-time PCR was carried out in a 7500 fast real-time 
PCR system (Applied Biosystems, Monza, IT) by Fast SYBR Green 
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Master Mix (cod. 4385610; Applied Biosystems, Monza, IT). Samples 
were amplified simultaneously in triplicate in one assay as follows: heating 
2 min @ 50º C, denaturation 10 min @ 95º C, amplification and 
quantification 35 cycles of 15 sec @ 95º C; 1 min @ 60º C with a single 
fluorescence measurement. PCR data was collected using ABI Prism 
7000 SDS software (Applied Biosystems). After PCR, products were 
electrophoretically separated on 1,5% agarose gels and bands were 
visualized with ethidium bromide and documented using a Gel Doc 
Imaging System (Bio-Rad, Hercules, CA). Normalization of the data was 
performed by HPRT as an internal control. Differences in mRNA content 
between groups were calculated as normalized values by using 2-ΔΔct 
formula and results were tested for significance using Relative Expression 
Software Tool (REST ©) [290]. The oligonucleotide sequences for NCX3 
and Hypoxanthine phosphoribosyltransferase (HPRT) were already 
published. 
III.5. Western Blotting 
For Western blot analysis, cells (or tissues) were collected in ice-cold lysis 
buffer [289] containing anti-protease cocktail (P8340 Sigma, Milan, IT). For 
HDAC4, HDAC5 (50 µg) and NCX3 (30 µg), proteins were separated on 
8% SDS polyacrylamide gels, whereas for DREAM expression, proteins 
(30 µg) were separated on 12% SDS-polyacrylamide gels. Both were 
transferred onto Hybond ECL nitrocellulose membranes (Amersham, 
Milan, IT). Membranes were blocked with 5% non fat dry milk in 0.1% 
Tween 20 (Sigma, Milan, IT) (2 mM Tris-HCl and 50 mM NaCl pH 7.5) for 
2 hours at room temperature, and then they were incubated overnight at 
4°C in the blocking buffer with the 1:1000 monoclonal antibodies against 
HDAC4 (sc-11418), HDAC5 (sc- 11419), DREAM (sc-9142) (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA),  and 1:2000 β-actin (A 4700) 
(Sigma, Milan, IT), 1:5000 α-tubulin (Sigma, Milan, IT), and NCX-3 (Swant, 
Bellinzona, Switzerland). Finally, after the incubation with primary 
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antibodies, membranes were washed with 0.1% Tween 20, followed by 
incubation with secondary antibodies for 1 h at room temperature. 
Immunoreactive bands were detected with the ECL reagent (Amersham). 
The optical density of the bands, normalized to β-actin, was determined by 
Chemi-Doc Imaging System (Bio-Rad, Hercules, CA). 
 
III.6. Chromatin Immunoprecipitation (ChIP)  
Brain tissue and cortical neurons were processed into chromatin by use of 
published protocols [289, 290] with some modifications. Cells and tissues 
were cross-linked with 1% formaldehyde, and then reaction was stopped 
by adding glycine to a final concentration of 0.125 M. Brain tissue and 
cells were washed three times in cold PBS containing proteinase inhibitors 
and then collected in a buffer containing: 50mM Tris pH 8.1, 1% SDS, 10 
mM EDTA, and anti-protease cocktail. For cell and tissue samples, 
chromatin was fragmented by sonication into 200–500 bp fragments (6 
rounds for cells and 15 rounds for brain tissue of 15 1-s pulses at 50% of 
maximum potency) by a Bandelin Sonopuls HD 2070 ultrasonic 
homogenizer (Bandelin, Berlin, Germany). Equal amounts of chromatin 
lysates (50 μg for cells and 70 μg for tissues) were incubated overnight 
with 5μg of antibody for HDAC4, HDAC5 (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), acetyl-Histone H4, RNA Polymerase II (Millipore, 
Milan, IT), and normal rabbit or mouse IgG were used as negative 
controls. After immunoprecipitation, the DNA-histone complex was 
collected with 40 μl of salmon sperm DNA/protein A or G -agarose beads 
for 2 hours (16-157, 16-201) (Millipore, Milan, IT). After rotating for 2 hours 
at 4°C on a spinning wheel, the beads were washed once with each of the 
following buffers in the order shown: high-salt buffer (0.1% SDS, 1% 
Triton, 2mM EDTA, 20mM Tris HCl pH 8.1, 500 mM NaCl); low-salt buffer 
(0.1% SDS, 1% Triton, 2mM EDTA, 20mM Tris HCl pH 8.1, 150mM NaCl); 
LiCl buffer (0.25M LiCl, 1% NP40, 1% deoxycholate, 1mM EDTA, 10mM 
Tris HCl pH 8.1), and two times at room temperature with TE buffer (10mM 
62 
 
Tris pH 8.1 and 1mM EDTA). The precipitated fragments were eluted with 
a buffer containing 1% SDS and 0.1M NaHCO3. DNA was analyzed by 
qRT-PCR using Fast SYBR Green Master Mix (cod 4385610; Applied 
Biosystems, Milan, IT). Heating 2 min @ 50ºC, denaturation 10 min @ 
95ºC, amplification and quantification 35 cycles of 30 sec @ 95ºC; 1 min 
@ 60°C with a single fluorescence measurement. The binding activity was 
graphically represented as the percentage of total input of chromatin and 
the results were analyzed using a previously described formula [291]. 
 The following oligonucleotides were used for the amplification of 
immunoprecipitated DNA:  A) Forward 5’-
CGAGGAGCGTTCTGAGAGTCTCC -3’ and Reverse 5’-
GCTTAGCGGTGACTGGAATCTACG -3’. For each amplification, melting 
curves and gel electrophoresis of the PCR product were used to verify 
their identities. Samples were amplified simultaneously in triplicate in one 
assay run. 
 
III.7. Experimental groups 
Male Sprague-Dawley rats (Charles River) weighing 250 to 300 g were 
housed under diurnal lighting conditions (12 h darkness/light). 
Experiments were performed according to the international guidelines for 
animal research. All experiments were approved by the Institutional 
Animal Care and Use Committee of the “Federico II” University of Naples, 
IT. 
 
III.8. Transient Focal Ischemia  
Transient focal ischemia was induced as previously described [155], by 
suture occlusion of the middle cerebral artery (MCA) in male rats 
anesthetized using 1.5% sevoflurane, 70% N2O, and 28.5% O2. 
Achievement of ischemia was confirmed by monitoring regional cerebral 
blood flow through laser Doppler (PF5001; Perimed). Animals not showing 
a cerebral blood flow reduction of at least 70% were excluded from the 
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study. Animals that did not show a cerebral blood flow reduction of at least 
70% were excluded from the experimental group, as well as animals that 
died after ischemia induction. Rats were divided into 2 experimental 
groups: (1) sham-operated (CTL); (2) ischemic, subjected to transient 
MCA occlusion (tMCAO). The sham-operated animals underwent the 
same experimental conditions except that the filament was not introduced; 
in the ischemic group, the MCA was occluded for 100 minutes. All animals 
were euthanized 24 h after the 100 min tMCAO. Rectal temperature was 
maintained at 37±0.5°C with a thermostatically controlled heating pad and 
a catheter was inserted into the femoral artery to measure arterial blood 
gases before and after ischemia (Rapid Laboratory 860, Chiron 
Diagnostic). All surgical procedures were performed under an operating 
stereomicroscope. 
 
III.9. Statistical analysis 
The data were evaluated as means ± SEM. Statistically significant 
differences among means were determined by ANOVA followed by 
Student-Newman-Keuls test. The threshold for statistical significance data 
was set at p<0.05. 
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IV RESULTS  
IV.1. HDAC class II A inhibitor MC1568 increases ncx3 promoter 
activity 
To evaluate whether a specific class of HDACs could regulate NCX3 
expression, experiments of luciferase assays were performed in neurons 
pre-treated for 2 hours with the pan-HDAC inhibitor Trichostatin A (TSA) at 
100 nM [292] or with class I HDAC inhibitor MS-275 at 5 μM [156], and 
with the class IIA HDAC inhibitor MC1568 at 5 μM [293]. For these 
experiments we used a pGL3 construct containing the human NCX3 
proximal promoter region named (pGL3-ncx3) already used in a previously 
paper [272]. At 24 hours TSA and MC1568 increased ncx3 promoter 
activity compared to cells transfected with pGL3-ncx3 alone. By contrast, 
no modification of NCX3 promoter activity was observed after MS-275 
pretreatment (Figure 4).  
 
Figure 4.  Effect of HDACI on ncx3 promoter activity. Cortical neurons were transfected with 
pGL3-ncx3 promoter and then treated with the pan-HDACI (TSA), with MS-275 an inhibitor for 
HDACs of class I and with MC1568 an HDACI specific for HDACs of class IIA. 24 hours post-
treatment, neurons were lysed in 1x passive lysis buffer. Lysates were analyzed for luciferase 
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activity. The luciferase activity was expressed as firefly-to-renilla ratio. Each column represents the 
mean ± s.e.m. of n=3 independent experiments (*P<0.05 vs pGL3-ncx3). 
 
IV.2. MC1568 increases ncx3 luciferase activity in time - dependent 
manner 
NCX3 lucifarase activity was significantly increased by MC1568 at 24 
hours compared to the cells transfected with pGL3-ncx3 alone. This 
increase in NCX3 luciferase activity reached a maximum after 48 h of 
incubation (Figure 5). 
 
Figure 5. Effect of MC1568 in time dependent manner on ncx3 promoter activity. Cortical 
neurons were transfected with pGL3-ncx3 promoter and then treated with MC1568 (5 µM) at 
different time. 24 hours post-treatment, neurons were lysed in 1x passive lysis buffer. Lysates were 
analyzed for luciferase activity. The luciferase activity was expressed as firefly-to-renilla ratio. Each 
column represents the mean ± s.e.m. of n=3 independent experiments (*P<0.05 vs pGL3-ncx3, 
**P<0.05 vs all). 
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IV.3. MC1568 regulates ncx3 promoter activity via DREAM sequence 
Luciferase assays were conducted to evaluate whether the DRE site 
(GTCAGTCA) and CRE site (GACGT) on ncx3 promoter were responsible  
of the MC1568-induced NCX3 increase. In particular, DREAM and CREB 
binding sites were mutated in the pGL3-ncx3 construct by site-directed 
mutagenesis to generate the pGL3-ncx3-DREmut (CACACACA) and 
pGL3-ncx3-CREmut (ACGGT) constructs. These two constructs were 
transfected in cortical neurons treated or not with MC1568 (5μM). The 
transfection of pGL3-ncx3-DREmut construct caused a significant increase 
of promoter activity compared to neurons transfected with pGL3-ncx3 
alone or transfected with pGL3-ncx3 and subsequently treated with 
MC1568. In neurons transfected with pGL3-ncx3 carrying mutations in 
DRE sites and treated with MC1568, ncx3 promoter activity was not 
increased significantly compared to cells transfected with pGL3-ncx3-
DREmut alone. The transfection of pGL3-ncx3-CREmut construct caused 
a significant decrease of promoter activity (Figure 6).  
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Figure 6. Effect of MC1568 on the transcriptional activity of the pGL3-ncx3 after site-directed 
mutagenesis of DREAM and CREB binding sites. Mutated nucleotides of ncx3 promoter are 
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underlined; replaced nucleotides are highlighted in yellow on the wild-type sequences. (a) Cortical 
neurons were transfected with pGL3-ncx3 wildtype or pGL3-ncx3-DREmut and then treated or not 
with MC1568. (b) Cortical neurons were transfected with pGL3-ncx3 wildtype or pGL3-ncx3-
CREmut. 24 hours post-transfection, neurons were lysed in 1x passive lysis buffer. Lysates were 
analyzed for luciferase activity. The luciferase activity was expressed as firefly-to-renilla ratio. Each 
column represents the mean ± s.e.m. of n=3 independent experiments. (*P<0.05 vs pGL3-ncx3, 
**P<0.05 vs all). 
 
IV.4. HDAC class IIA isoforms 4 and 5 reduce NCX3 mRNA and 
protein expression 
HDAC Class IIa is composed of HDAC 4, 5, 7 and 9 [122]. Thus, to detect 
which of these isoforms was possibly involved in the MC1568-dependent  
increase of NCX3 mRNA and protein, neurons were silenced by specific 
siRNAs against HDAC 4, 5, 7 and 9 named siHDAC4, siHDAC5, siHDAC7 
and siHDAC9. 
Real Time PCR (qRT–PCR) at 24 hours and western blot analysis at 48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
hours revealed that in neurons, NCX3 mRNA and protein increased with 
siHDAC4 and with siHDAC5 whereas any changing was detected with 
siHDAC7 and siHDAC9 all compared to Control (CTL).  
To further confirm the role of HDAC4 and HDAC5 in regulating NCX3 
expression, neurons were transfected with constructs overexpressing 
HDAC 4, 5, 7 and 9. In neurons overexpressing HDAC4 and HDAC5, 
NCX3 mRNA and protein were both reduced whereas cells 
overexpressing the other two HDAC isoforms belonging to class IIA did 
note determine any modification of NCX3 (Figure 7). 
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a                                                                                    b 
     
 
c                                                            d 
 
                                                         
Figure 7. Effects of HDACs class IIA on ncx3 gene and protein. (a,c). qRT–PCR and 
representative WB with quantification of NCX3 in cortical neurons transfected with constructs for 
HDAC4, HDAC5, HDAC7 and HDAC9. Each column represents the mean ± s.e.m. of n=3 
independent experiments (*P<0.05 vs CTL). (b,d). qRT–PCR and representative WB with 
quantification of NCX3 in cortical neurons transfected with siHDAC4, siHDAC5, siHDAC7 and 
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siHDAC9.  Each column represents the mean ± s.e.m. of n=3 independent experiments (*P<0.05 vs 
CTL). 
                          
IV.5. DREAM, HDAC4 and HDAC5 protein expression   
is increased in brain ischemia 
NCX3 isoform has been deeply investigated in the pathophysiology of 
stroke. In particular it has been found that its knock-down worsens the 
ischemic damage or reduces preconditioning-induced neuroprotection, 
respectively [265,281]. Western blot analysis, performed in the cortex of 
rats at 24 and 48 h after tMCAO, revealed a significative increase of 
DREAM, HDAC4 and HDAC5 in parallel with a reduction of NCX3 protein 
(Figure 8). 
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Figure 8. Effect of tMCAO on DREAM, HDAC4, HDAC5 and NCX3 expression. (a, b, c, d) 
Representative WB with quantification of DREAM, HDAC4, HDAC5 and NCX3 protein expression 
in: (1) control group (CTL), (2) tMCAO at 24h and (3) tMCAO at 48h. Each column represents the 
mean ± s.e.m. (n= 5 animals for each column) (*P<0.05 vs CTL).  
 
IV.6. Stroke induces an increase of HDAC4 and HDAC5 binding on 
ncx3 promoter 
The deacetylation of histones is a modification associated generally to 
transcriptional repression that is achieved through the reduction of access 
of the transcription machinery to the genes [67]. By ChIP analysis we 
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found that tMCAO determined at level of the ncx3 promoter sequence an 
increase of the binding of DREAM, HDAC4 and HDAC5 and a reduction of 
the amount  of the ncx3 promoter associated with acetylated histone H4 
protein and RNA-Pol II (Figure 9).  
 
Figure 9. Stroke induces transcriptional modifications on ncx3 promoter.  ChIP analysis with 
anti-HDAC4, HDAC5, anti- H4acetyl and anti- RNA polymerase II of ncx3 promoter in CTL and  in 
tMCAO. IgG was used as negative control. Each column represents the mean ± s.e.m. (n= 5 
animals for each column) (*P<0.05 vs CTL). 
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V DISCUSSION 
 
The results of this thesis indicate that in rat cortical neurons ncx3 
luciferase activity is increased by the class IIa HDAC inhibitor MC1568, 
but not by the class I inhibitor MS-275. Furthermore, the effect of MC1568 
on NCX3 promoter activity occurs via DREAM sequence. Among the 
HDAC class IIA only HDAC4 and HDAC5 isoforms are able to regulate 
ncx3 expression. In addition, during brain ischemia HDAC4 and 5 were 
increased in parallel with a reduction of NCX3.  
Many studies demonstrated that the ODNs, not only for NCX1 but also for 
NCX3 gene product, caused a worsening of ischemic damage in animals 
subjected to pMCAO [265] and that NCX3 may play a great protective role 
in chemical hypoxia since it seems to be the unique isoform of the 
exchanger able to function in spite of ATP depletion [266]. 
NCX3 is neuroprotective in brain ischemia, in fact knockout mice ncx3-/-  
displayed a worsening of neuronal death after an ischemic insult [267]. 
About transcriptional regulation of NCX3 it has been found that after 
ischemia NCX3 mRNA expression was reduced approximately of 50% at 
24 hours [281] while in ischemic postconditionig ncx3 mRNA is increased 
of about 40%[154,281]. Recently it has been found that in preconditioned 
rats NCX3 protein reduction is blocked by the binding of SUMO-1 at 72 
hours after ischemia [287]. Previous studies demonstrated that MC1568 
by regulating HDAC4 reverts DEHP-induced neuronal cell death [294] and 
protects neural processes against neurotoxic insult [295] .  
A crucial finding of this work is that only HDAC4 and HDAC5 isoforms are 
able to regulate the transcription and the expression of NCX3. 
Interestingly, the other two isoforms belonging to the HDAC class IIA 
HDAC7 and 9, did not change the expression of NCX3. NCX3 promoter 
has putative consensus sequences for the CRE binding protein (CREB) 
and for the Ca2+-binding protein downstream regulatory element (DRE) 
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antagonist modulator (DREAM) [275]. CRE sequence is involved in the 
stimulation of ncx3 promoter [275], whereas DRE sequence for its 
repression [272].  We found that mutation of DRE and CRE sequences 
causes an increase or a reduction of ncx3 promoter activity, respectively. 
Specifically, MC1568 by inhibiting HDAC class IIA increases NCX3 
promoter activity via DREAM sequence, indeed mutation of DRE  
sequence on ncx3 promoter (pGL3-ncx3-DREmut) together with HDAC 
class IIA inhibition due to MC1568 treatment did not cause any significant 
effect compared to pGL3-ncx3-DREmut. 
About DREAM and HDAC4, it has been reported that the former is a 
repressor of NCX3 transcription [272], whereas the latter is a mediator of 
neuronal cell death. Indeed, the exposure of cultured cerebellar granule 
neurons (CGNs) to low potassium medium, reported as apoptotic stimulus, 
triggers rapidly the translocation of HDAC4 into the nucleus with 
subsequent neuronal death [296]. Interestingly we found that DREAM, 
HDAC4 and HDAC5 protein expression is increased at 24h and 48h after 
brain ischemia. NCX3 isoform has been deeply investigated in the 
pathophysiology of stroke. In particular, we found that  the increase in the 
expression of HDAC4, HDAC5 and DREAM occurred in parallel with the 
NCX3 reduction. The deacetylation of histones is an epigenetic 
modification determining a transcriptional repression due to restricted  
access of the transcriptional machinery to the promoter regions of genes 
[67]. In particular, by ChIP analysis we found that in brain ischemia 
HDAC4 and HDAC5 are recruited to ncx3 promoter decreasing H4 
acetylation and RNA-Pol II binding. By these experiments it could be 
hypothesized that HDAC4 and HDAC5 by binding ncx3 promoter could 
lead to ncx3 reduction and consequent neuronal cell death. Collectively, 
these data demonstrate that MC1568 increases ncx3 promoter activity 
through DRE site and that the transcription factor DREAM by recruiting 
HDAC4 and 5 could reduce ncx3 mRNA and protein expression at basal 
level and in brain ischemia. Intriguingly, the development of new HDACs 
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inhibitors specific for each isoform can be considered a new step for the 
improvement of therapeutic strategies against cerebral ischemia and all 
neurodegenerative diseases where HDACs-increased activity or 
expression are involved. 
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